Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

22
results for

"Kidney"

Article category

Keywords

Publication year

"Kidney"

Correspondence

Incorporating chronic kidney disease into the cost-effectiveness of MASLD treatment
Eileen L. Yoon, Jeong-Yeon Cho, Mimi Kim, Huiyul Park, Hye-Lin Kim, Dae Won Jun
Received January 20, 2026  Accepted January 24, 2026  Published online February 2, 2026  
DOI: https://doi.org/10.3350/cmh.2026.0099    [Accepted]
  • 458 View
  • 30 Download

Review

Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury: chronic kidney disease spectrum
Vishnu Girish, Rakhi Maiwall
Clin Mol Hepatol 2025;31(3):730-752.
Published online March 26, 2025
DOI: https://doi.org/10.3350/cmh.2024.1060
Kidney disease in cirrhosis is now viewed as a continuum encompassing acute kidney injury (AKI), acute kidney disease (AKD), and chronic kidney disease (CKD), rather than three different disorders. Contemporary diagnostic criteria for AKI integrate urine output (UO) parameters and acknowledge the intricate relationship and possibility of overlap between functional and structural as well as acute and chronic entities, including hepatorenal syndrome (HRS). AKI demonstrates a propensity for progression to AKD and CKD, particularly in the context of recurrent and severe insults. The diagnostic complexity is further compounded by limitations in serum creatinine measurements, prompting the integration of novel biomarkers and the need to accurately estimate glomerular filtration rate. The diagnosis, phenotyping, and management of AKI should be prompt and early; the initial step should always be volume and UO assessment. A personalized approach is needed and the possibility of co-existing structural or functional kidney disease should be borne in mind. The earlier concept of waiting for 48 hours to diagnose HRS has evolved and early diagnosis and prompt treatment are advised now. Kidney replacement therapy and simultaneous liver and kidney transplantation may be required in resistant cases.

Citations

Citations to this article as recorded by  Crossref logo
  • Comprehensive Conservative Management Versus Dialysis in Uric Acid Control
    Francesca K. Martino, Greta Redi, Marco Bogo, Elena Sgrò, Alessandra Zattarin, Giovanni Samassa, Lucia Federica Stefanelli, Anna Basso, Federico Nalesso
    Dietetics.2026; 5(1): 9.     CrossRef
  • Renal Recovery Benefit of Living Versus Deceased Donor Liver Transplantation in Recipients With High Model for End-Stage Liver Disease Scores: A Propensity Score-matched Study
    Sung-Min Kim, Rak-Kyun Oh, Young-In Yoon, Won-Mook Choi, Shin Hwang, Ki-Hun Kim, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Sung-Gyu Lee
    Transplantation.2026;[Epub]     CrossRef
  • Early prediction of acute kidney injury after therapeutic paracentesis in decompensated liver cirrhosis: diagnostic value of IL-18, KIM-1, and FGF-23
    Ahmed Fayed, Ahmed Ramadan, Tarek Ramzy, Amr Shaker
    Renal Failure.2026;[Epub]     CrossRef
  • Risk factors for acute kidney injury in pediatric intensive care units: a systematic review and meta-analysis
    Rong Li, Qianqian Yang
    BMC Pediatrics.2026;[Epub]     CrossRef
  • Association between the C-reactive protein–triglyceride–glucose index (CTI) and the risk of acute kidney injury in critically ill patients with cirrhosis
    Lu-Huai Feng, Tianbao Liao, Tingting Su, Xuefei Zhou, Yang Lu, Lina Huang, Zhenhua Yang
    BMC Nephrology.2025;[Epub]     CrossRef
  • 10,585 View
  • 247 Download
  • 3 Web of Science
  • Crossref

Correspondences

Liver Transplantation

  • 6,029 View
  • 36 Download

Editorial

Liver Transplantation

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
    Soon Kyu Lee, Jong Young Choi
    Clinical and Molecular Hepatology.2025; 31(2): e161.     CrossRef
  • 6,468 View
  • 50 Download
  • 1 Web of Science
  • Crossref

Letter to the Editor

Liver Transplantation

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
    Soon Kyu Lee, Jong Young Choi
    Clinical and Molecular Hepatology.2025; 31(2): e212.     CrossRef
  • 6,844 View
  • 48 Download
  • 1 Web of Science
  • Crossref

Review

Steatotic liver disease

Bioactive metabolites: A clue to the link between MASLD and CKD?
Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun
Clin Mol Hepatol 2025;31(1):56-73.
Published online October 21, 2024
DOI: https://doi.org/10.3350/cmh.2024.0782
Metabolites produced as intermediaries or end-products of microbial metabolism provide crucial signals for health and diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD). These metabolites include products of the bacterial metabolism of dietary substrates, modification of host molecules (such as bile acids [BAs], trimethylamine-N-oxide, and short-chain fatty acids), or products directly derived from bacteria. Recent studies have provided new insights into the association between MASLD and the risk of developing chronic kidney disease (CKD). Furthermore, alterations in microbiota composition and metabolite profiles, notably altered BAs, have been described in studies investigating the association between MASLD and the risk of CKD. This narrative review discusses alterations of specific classes of metabolites, BAs, fructose, vitamin D, and microbiota composition that may be implicated in the link between MASLD and CKD.

Citations

Citations to this article as recorded by  Crossref logo
  • Radish Green Extract Attenuates Western Diet-Induced Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice
    Hye-Bin Lee, Yu Ra Lee, Eunjung Lee, Seong Un Jeong, Jae-Hyun Yoon, Miri Park, Yoonsook Kim, Ho-Young Park
    Journal of Agricultural and Food Chemistry.2026; 74(1): 874.     CrossRef
  • Multi-omics reveal the key role of gut microbiota metabolism in adenine-induced chronic kidney disease
    Yijing Xin, Hui Ma, Xiang Li, Ruiyang Sun, Luo Fang, Libin Pan
    Toxicology and Applied Pharmacology.2026; 509: 117754.     CrossRef
  • Research Progress on the Bile Acid Metabolome in Arteriovenous Fistula Stenosis among Maintenance Hemodialysis Patients
    佩 张
    Advances in Clinical Medicine.2026; 16(03): 2204.     CrossRef
  • Creatinine clearance rate predicts all-cause and cardiovascular mortality in patients with MASLD: a Shanghai cohort study
    Yingqi Hou, Yanqiu Huang, Chenghao Zhang, Wen Gu, Yadan Xu, Shuli Li, Jugang Wu, Jibin Liu, Honglin Liu
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges
    Dario Piatto, Delia De Biasio, Francesco Giustino Cesaro, Gianmario Forcina, Vittoria Frattolillo, Antonio Colucci, Fabio Lamberti, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa
    Journal of Clinical Medicine.2025; 14(11): 3911.     CrossRef
  • Altered mitochondrial function: a clue therapeutic strategies between metabolic dysfunction-associated steatotic liver disease and chronic kidney disease?
    Jiang Bai, Lijuan Zhang, Letian He, Yun Zhou
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review
    Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi
    Nutrients.2025; 17(13): 2211.     CrossRef
  • Quyu Huazhuo Decoction alleviates non-Alcoholic steatohepatitis via remodeling the gut microbiota and regulating bile acid and short-chain fatty acid metabolism
    Lu Lu, Chengting Wu, Juhong Jia, Yuanqin Du, Yujiao Peng, Hongna Huang, Jingjing Huang, Yaobin Nong
    Journal of Chromatography B.2025; 1267: 124784.     CrossRef
  • The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management
    Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano
    Exploration of Medicine.2025;[Epub]     CrossRef
  • Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications
    Wenhua Bai, Zheng Zhu
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis are Associated with Advanced Cardiovascular-Kidney-Metabolic Syndrome in Chinese and US Populations
    Shidi Hu, Dongmei Wang, Qingtao Yu, Zhi Chen, Weiguo Lu, Yuan Meng, Xuetao Peng, Lan Liu, Heng Wan, Jie Shen
    Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 4699.     CrossRef
  • 9,575 View
  • 246 Download
  • 9 Web of Science
  • Crossref

Original Article

Liver Transplantation

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation
Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, Pil Soo Sung, Seung Kew Yoon, Jeong Won Jang, Jong Young Choi
Clin Mol Hepatol 2025;31(1):131-146.
Published online October 2, 2024
DOI: https://doi.org/10.3350/cmh.2024.0451
Background/Aims
This study aimed to identify the risk factors for chronic kidney disease (CKD) and end-stage renal disease (ESRD) following liver transplantation (LT), with a specific focus on tacrolimus levels and intrapatient variability (IPV).
Methods
Among the 1,076 patients who underwent LT between 2000 and 2018, 952 were included in the analysis. The tacrolimus doses and levels were recorded every 3 months, and the IPV was calculated using the coefficient of variability. The cumulative incidence rates of CKD and ESRD were calculated based on baseline kidney function at the time of LT. The impact of tacrolimus levels and their IPV on the development of CKD and ESRD was evaluated, and the significant risk factors were identified.
Results
Within a median follow-up of 97.3 months, the 5-year cumulative incidence rates of CKD (0.58 vs. 0.24) and ESRD (0.07 vs. 0.01) were significantly higher in the acute kidney injury group than in the normal glomerular filtration rate (GFR) group. In the normal GFR group, the tacrolimus levels were identified as a risk factor for CKD, with a level of ≤4.5 ng/mL suggested as optimal for minimizing the risk of CKD. Furthermore, the IPV of tacrolimus levels and doses emerged as a significant risk factor for CKD development in both groups (p<0.05), with tenofovir disoproxil fumarate also being a risk factor in HBV-infected patients. The IPV of tacrolimus levels was also a significant factor in ESRD development (p<0.05).
Conclusions
This study elucidated the optimal tacrolimus trough level and highlighted the impact of IPV on the CKD and ESRD development post-LT.

Citations

Citations to this article as recorded by  Crossref logo
  • Schisandrin B alleviates liver allograft rejection by stabilizing ACOD1 in Kupffer cells to potentiate itaconate-NRF2-mediated suppression of CD8+ T cell chemotaxis
    Yihua Wang, Dadi Peng, Dengliang Lei, Liqing Jiang, Song Xiang, Qiuying Li, Hong Zhang, Zhongjun Wu, Chao Yu, Tengxiang Chen
    Phytomedicine.2026; 154: 158031.     CrossRef
  • Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development foll
    Jongman Kim
    Clinical and Molecular Hepatology.2025; 31(2): 589.     CrossRef
  • Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
    Soon Kyu Lee, Jong Young Choi
    Clinical and Molecular Hepatology.2025; 31(2): e212.     CrossRef
  • Clinical significance and gene prediction of a novel classification system based on tacrolimus concentration-to-dose ratio in the early post-liver transplant period
    Junwei Fan, Peihao Wen, Liyun Yuan, Yan Xia, Shijie Hu, Xiaoqing Zhang, Zhihai Peng
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Chronic kidney disease at one year after liver transplantation: Role of changes in immunosuppression over three decades
    Alejandro Muñoz-Serrano, María Jesús Citores, Andrea Gutiérrez-Villanueva, Víctor Moreno-Torres, Jorge V López-Ibor, Natalia Vicente, Valentín Cuervas-Mons
    World Journal of Transplantation.2025;[Epub]     CrossRef
  • 11,177 View
  • 223 Download
  • 6 Web of Science
  • Crossref

Letter to the Editor

Steatotic liver disease

Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
Clin Mol Hepatol 2024;30(4):962-964.
Published online May 20, 2024
DOI: https://doi.org/10.3350/cmh.2024.0264

Citations

Citations to this article as recorded by  Crossref logo
  • Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10‐year follow‐up period
    Kazuma Mori, Marenao Tanaka, Tatsuya Sato, Yukinori Akiyama, Keisuke Endo, Toshifumi Ogawa, Toru Suzuki, Hiroki Aida, Wataru Kawaharata, Kei Nakata, Itaru Hosaka, Araya Umetsu, Nagisa Hanawa, Masato Furuhashi
    Hepatology Research.2025; 55(1): 34.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases
    Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen
    Annals of Hepatology.2025; 30(1): 101750.     CrossRef
  • Chronic Kidney Disease Risk Associated With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Cohort Study in Korea
    Dong Wook Kim, Minkook Son, Hye Jung Lee, Chi Hyeon Choi, Yeo Wool Kang, Sang Yi Moon, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek, Won Suk An
    Hepatology Research.2025; 55(9): 1239.     CrossRef
  • Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific region
    Pojsakorn Danpanichkul, Kanokphong Suparan, Banthoon Sukphutanan, Chuthathip Kaeosri, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Markos Kalligeros, Natchaya Polpichai, Yanfang Pang, Karn Wijarnpreecha, Pimsiri Sripongpun, Naichaya Chamroonkul, M
    Scientific Reports.2024;[Epub]     CrossRef
  • Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3
    Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Naohiro Komatsu, Sayuri Sugio, Miruki Yoshino, Hisamitsu Miyaaki
    Internal Medicine.2024;[Epub]     CrossRef
  • 5,723 View
  • 120 Download
  • 5 Web of Science
  • Crossref

Reviews

Liver fibrosis, cirrhosis, and portal hypertension

Hepatorenal syndrome: Current concepts and future perspectives
Chan-Young Jung, Jai Won Chang
Clin Mol Hepatol 2023;29(4):891-908.
Published online April 13, 2023
DOI: https://doi.org/10.3350/cmh.2023.0024
Hepatorenal syndrome (HRS), a progressive but potentially reversible deterioration of kidney function, remains a major complication in patients with advanced cirrhosis, often leading to death before liver transplantation (LT). Recent updates in the pathophysiology, definition, and classification of HRS have led to a complete revision of the nomenclature and diagnostic criteria for HRS type 1, which was renamed HRS-acute kidney injury (AKI). HRS is characterized by severe impairment of kidney function due to increased splanchnic blood flow, activation of several vasoconstriction factors, severe vasoconstriction of the renal arteries in the absence of kidney histologic abnormalities, nitric oxide dysfunction, and systemic inflammation. Diagnosis of HRS remains a challenge because of the lack of specific diagnostic biomarkers that accurately distinguishes structural from functional AKI, and mainly involves the differential diagnosis from other forms of AKI, particularly acute tubular necrosis. The optimal treatment of HRS is LT. While awaiting LT, treatment options include vasoconstrictor drugs to counteract splanchnic arterial vasodilation and plasma volume expansion by intravenous albumin infusion. In patients with HRS unresponsive to pharmacological treatment and with conventional indications for kidney replacement therapy (KRT), such as volume overload, uremia, or electrolyte imbalances, KRT may be applied as a bridging therapy to transplantation. Other interventions, such as transjugular intrahepatic portosystemic shunt, and artificial liver support systems have a very limited role in improving outcomes in HRS. Although recently developed novel therapies have potential to improve outcomes of patients with HRS, further studies are warranted to validate the efficacy of these novel agents.

Citations

Citations to this article as recorded by  Crossref logo
  • Paracentesis exceeding three liters increases risks of acute kidney injury even in cirrhotic patients with albumin infused refractory ascites
    Pei-Shan Wu, Kuei-Chuan Lee, Chih-Yu Li, Yun-Cheng Hsieh, Teh-Ia Huo, Han-Chieh Lin, Ming-Chih Hou
    Journal of the Formosan Medical Association.2026; 125(3): 268.     CrossRef
  • Outcomes of Highly Urgent ABO-Incompatible Living Donor Liver Transplantation in National Databases
    Jongman Kim, Sang Jin Kim, Boram Park, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Seung Heui Hong, Soon-Young Kim, Jungbun Park, Youngwon Hwang, Dong-Hwan Jung
    Journal of Korean Medical Science.2026;[Epub]     CrossRef
  • Rising mortality due to coexisting liver cirrhosis and kidney failure in the United States (1999–2023): A nationwide retrospective analysis
    Muhammad Shaheer Bin Faheem, Syed Tawassul Hassan, Syeda Umbreen Munir, Muhammad Idrees Khan
    Medicine.2026; 105(9): e47662.     CrossRef
  • Neurofilament light chain proteins are a sensitive biomarker of neuronal damage in cirrhotic patients with hepatic encephalopathy
    Clelia Asero, Francesca Polito, Maria Stella Franzé, Antonio Battaglia, Claudia Ligresti, Teresa Maltese, Irene Cacciola, M’Hammed Aguennouz, Vincenzo Macaione
    Frontiers in Molecular Biosciences.2026;[Epub]     CrossRef
  • Trends and Demographics of Hepatorenal Syndrome-Related Mortality in the U.S., 1999–2024: A CDC WONDER Analysis
    Syed Faisal Ali, Julia Natche, Mahendrakumar Achlaram Chaudhari, Hassan Abbasi, Sammy Dawoud, Hany Dawoud, Amna Shoaib, Hersh Tilokani, Harleen Kaur Chela, Arsal Zafar
    Diseases.2026; 14(3): 106.     CrossRef
  • Association of visceral fat obesity with structural change in abdominal organs: fully automated three-dimensional volumetric computed tomography measurement using deep learning
    Haruka Kiyoyama, Masahiro Tanabe, Mayumi Higashi, Naohiko Kamamura, Yosuke Kawano, Kenichiro Ihara, Keiko Hideura, Katsuyoshi Ito
    Abdominal Radiology.2025; 50(9): 4395.     CrossRef
  • Understanding and Treating Hepatorenal Syndrome: Insights from Recent Research
    Yuli Song, Xiaochen Yang, Chengbo Yu
    Seminars in Liver Disease.2025; 45(03): 328.     CrossRef
  • Ascites complications risk factors of decompensated cirrhosis patients: logistic regression and prediction model
    Xiaolong Zheng, Wei Wei
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Emergency living donor liver transplantation
    Jongman Kim
    Annals of Liver Transplantation.2025; 5(1): 27.     CrossRef
  • Assessment of Albumin Therapy and Paracentesis Interval in Cirrhotic Patients With Recurrent Ascites: A Prospective Cohort Study
    Muhammad Abdullah Khan, Hafiz Muhammad Faizan Mughal, Shehwar Ahmed, M Khaliq, Abdul Ghafoor
    Cureus.2025;[Epub]     CrossRef
  • Acute Kidney Injury in Patients with Liver Cirrhosis: From Past to Present Definition and Diagnosis
    Andreea Lungu, Georgiana-Elena Sarbu, Alexandru Sebastian Cotlet, Ilie-Andreas Savin, Ioana-Roxana Damian, Simona Juncu, Cristina Muzica, Irina Girleanu, Ana-Maria Sîngeap, Carol Stanciu, Anca Trifan, Camelia Cojocariu
    Life.2025; 15(8): 1249.     CrossRef
  • Oral Branched-Chain Amino Acids as a Cost-Effective Option for Managing Hepatic Encephalopathy
    Hankil Lee, Sang Hoon Ahn, Beom Kyung Kim
    Yonsei Medical Journal.2025; 66(11): 713.     CrossRef
  • Life after hepatorenal syndrome: unraveling quality of life, psychological distress, and treatment preferences
    J. Müller-Kühnle, M. Schanz, J. Latus, D. Marschner, S. Schricker
    BMC Palliative Care.2025;[Epub]     CrossRef
  • The Kidney in the Shadow of Cirrhosis: A Critical Review of Renal Failure
    Livia-Mirela Popa, Paula Anderco, Oana Stoia, Cristian Ichim, Corina Porr
    Biomedicines.2025; 13(11): 2775.     CrossRef
  • Predicting risk factors for waiting mortality in adult emergent living donor liver transplantation based on Korean national data
    Sang Jin Kim, Jongman Kim, Kyunga Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
    Annals of Liver Transplantation.2025; 5(2): 107.     CrossRef
  • VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis
    Shohei Asada, Tadashi Namisaki, Kosuke Kaji, Hiroaki Takaya, Takahiro Kubo, Takemi Akahane, Hideto Kawaratani, Norihisa Nishimura, Soichi Takeda, Hiroyuki Masuda, Akihiko Shibamoto, Takashi Inoue, Satoshi Iwai, Fumimasa Tomooka, Yuki Tsuji, Yukihisa Fujin
    Digestive Diseases and Sciences.2024; 69(3): 851.     CrossRef
  • Gut Microbiota and Biomarkers of Endothelial Dysfunction in Cirrhosis
    Irina Efremova, Roman Maslennikov, Elena Poluektova, Oleg Medvedev, Anna Kudryavtseva, George Krasnov, Maria Fedorova, Filipp Romanikhin, Vyacheslav Bakhitov, Salekh Aliev, Natalia Sedova, Tatiana Kuropatkina, Anastasia Ivanova, Maria Zharkova, Ekaterina
    International Journal of Molecular Sciences.2024; 25(4): 1988.     CrossRef
  • Infection-Related Readmissions Are Rising among Patients with Hepatorenal Syndrome: A Nationwide Analysis
    Umer Farooq, Zahid I. Tarar, Ammad J. Chaudhary, Abdallah E. Alayli, Faisal Kamal, Chengdu Niu, Kamran Qureshi
    Livers.2024; 4(2): 268.     CrossRef
  • Management of hepatorenal syndrome and treatment-related adverse events
    Lorenzo Peluso, Marzia Savi, Giacomo Coppalini, Deliana Veliaj, Nicola Villari, Giovanni Albano, Stephen Petrou, Maria C. Pace, Marco Fiore
    Current Medical Research and Opinion.2024; 40(7): 1155.     CrossRef
  • Features of the course of hepatorenal syndrome in decompensated portal hypertension (case report)
    M.I. Tutchenko, D.V. Rudyk, M.S. Besedinskyi, S.L. Chub, Yu.V. Nerushchenko
    GASTROENTEROLOGY.2024; 58(2): 151.     CrossRef
  • Protective effect of long-chain polyunsaturated fatty acids on hepatorenal syndrome in rats
    João Bruno Beretta Duailibe, Cassiana Macagnan Viau, Jenifer Saffi, Sabrina Alves Fernandes, Marilene Porawski
    World Journal of Nephrology.2024;[Epub]     CrossRef
  • Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function
    Xingyue Huang, Jas Bindra, Ishveen Chopra, John Niewoehner, George J. Wan
    Advances in Therapy.2023; 40(12): 5432.     CrossRef
  • 18,122 View
  • 1,512 Download
  • 21 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Current knowledge about biomarkers of acute kidney injury in liver cirrhosis
Han Ah Lee, Yeon Seok Seo
Clin Mol Hepatol 2022;28(1):31-46.
Published online August 2, 2021
DOI: https://doi.org/10.3350/cmh.2021.0148
Acute kidney injury (AKI) is common in advanced cirrhosis. Prerenal azotemia, hepatorenal syndrome, and acute tubular necrosis are the main causes of AKI in patients with cirrhosis. Evaluation of renal function and differentiation between functional and structural kidney injury are important issues in the management of cirrhosis. However, AKI in cirrhosis exists as a complex clinical spectrum rather than concrete clinical entity. Based on current evidence, changes in serum creatinine (Cr) levels remain the most appropriate standard for defining AKI in cirrhosis. However, serum Cr has a limited role in assessing renal function in this population. This review examines previous studies that investigated the ability of recent biomarkers for AKI in cirrhosis from the perspective of earlier and accurate diagnosis, classification of AKI phenotype, and prediction of clinical outcomes. Serum cystatin C and urine neutrophil gelatinase-associated lipocalin have been extensively studied in cirrhosis, and have facilitated improved diagnosis and prognosis prediction in patients with AKI. In addition, urine N-acetyl-β-D-glucosaminidase, interleukin 18, and kidney injury molecule 1 are other promising biomarkers for advanced cirrhosis. However, the clinical significance of these markers remains unclear because there are no cut-off values defining the normal range and differentiating phenotypes of AKI. In addition, AKI has been defined in terms of serum Cr, and renal biopsy—the gold standard—has not been carried out in most studies. Further discovery of innovate biomarkers and incorporation of various markers could improve the diagnosis and prognosis prediction of AKI, and will translate into meaningful improvements in patient outcomes.

Citations

Citations to this article as recorded by  Crossref logo
  • The Value of T1 and T2 Mapping in Diagnosing Chronic Liver Disease–related Kidney Injury and Monitoring the Outcome of Stem Cell Therapy: An Animal Experimental Study
    Jiaming Qin, Hongtao Yuan, Chao Wang, Yue Wang, Dan Tong, Zhandong Hu, Chen Zhang, Wen Shen, Shuangshuang Xie
    Magnetic Resonance in Medical Sciences.2026;[Epub]     CrossRef
  • Evaluation of Acute Kidney Injury (AKI) Biomarkers FABP1, NGAL, Cystatin C and IL-18 in an Indian Cohort of Hospitalized Acute-on-chronic Liver Failure (ACLF) Patients
    Rohini Saha, Samriddhi Sharma, Antara Mondal, Hem C. Sati, Maroof A. Khan, Sandeep Mahajan, Sudip Datta, Shalimar, Pragyan Acharya
    Journal of Clinical and Experimental Hepatology.2025; 15(3): 102491.     CrossRef
  • The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review
    Mohammed Yousef Almulhim, Gianpaolo Reboldi
    PLOS ONE.2025; 20(1): e0311755.     CrossRef
  • Neutrophil gelatinase–associated lipocalin for predicting acute kidney injury in orthotopic liver transplantation: a systematic review and meta-analysis
    Fangran Yan, Zenghua Zhou, Xueke Du, Sheng He, Linghui Pan
    European Journal of Gastroenterology & Hepatology.2025; 37(6): 683.     CrossRef
  • Understanding acute kidney injury in cirrhosis: Current perspective
    Sayan Malakar, Sumit Rungta, Arghya Samanta, Umair Shamsul Hoda, Piyush Mishra, Gaurav Pande, Akash Roy, Suprabhat Giri, Praveer Rai, Samir Mohindra, Uday C Ghoshal
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Protective effects of Katsuwonus pelamis hydrolysates against renal injury: Val-Lys as a potent renoprotective peptide
    Ying Cheng, Mingjie Zhou, Zishan Hong, Lin Zheng, Mouming Zhao
    Food & Function.2025; 16(13): 5616.     CrossRef
  • Acute Kidney Injury in Patients with Liver Cirrhosis: From Past to Present Definition and Diagnosis
    Andreea Lungu, Georgiana-Elena Sarbu, Alexandru Sebastian Cotlet, Ilie-Andreas Savin, Ioana-Roxana Damian, Simona Juncu, Cristina Muzica, Irina Girleanu, Ana-Maria Sîngeap, Carol Stanciu, Anca Trifan, Camelia Cojocariu
    Life.2025; 15(8): 1249.     CrossRef
  • The Value of Diffusion Kurtosis Imaging to Assess Liver and Kidney Recovery after Mesenchymal Stem Cell Intervention in CCl4-Induced Cirrhotic Rats
    Jiaming Qin, Shuangshuang Xie, Yongquan Yu, Cheng Zhang, Yumeng Zhao, Dan Tong, Zhandong Hu, Jinxia Zhu, Wen Shen
    American Journal of Nephrology.2025; 56(4): 475.     CrossRef
  • CIRROSE HEPÁTICA EM ESTÁGIO AVANÇADO E O PAPEL DO TRANSPLANTE DE FÍGADO: DESAFIOS ATUAIS E PERSPECTIVAS FUTURAS NO MANEJO DE PACIENTES COM DOENÇA HEPÁTICA TERMINAL
    Gabriel Duarte do Nascimento, Gustavo Ribeiro Mesquita, Gilson Augusto Nunes Martins Pombeiro
    Revista Contemporânea.2025; 5(8): e8869.     CrossRef
  • Nationwide analysis of renal outcomes in chronic hepatitis B patients treated with Tenofovir Alafenamide vs. Entecavir
    Hyuk Kim, Jae Young Kim, Hye-Jin Yoo, Log Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Association between the C-reactive protein–triglyceride–glucose index (CTI) and the risk of acute kidney injury in critically ill patients with cirrhosis
    Lu-Huai Feng, Tianbao Liao, Tingting Su, Xuefei Zhou, Yang Lu, Lina Huang, Zhenhua Yang
    BMC Nephrology.2025;[Epub]     CrossRef
  • Delhi Model: A New Tool for Predicting Response to Terlipressin in Hepatorenal Syndrome—Acute Kidney Injury
    Jatin Agrawal, Ashish Kumar, Praveen Sharma, Naresh Bansal, Vikas Singla, Samarth Sharma, Anil Arora
    Journal of Clinical and Experimental Hepatology.2024; 14(1): 101266.     CrossRef
  • Fibrotic Burden in Patients With Hepatitis B Virus–Related Cirrhosis Is Independently Associated With Poorer Kidney Outcomes
    Chan-Young Jung, Hui-Yun Jung, Hyung Woo Kim, Geun Woo Ryu, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    The Journal of Infectious Diseases.2024; 229(1): 108.     CrossRef
  • VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis
    Shohei Asada, Tadashi Namisaki, Kosuke Kaji, Hiroaki Takaya, Takahiro Kubo, Takemi Akahane, Hideto Kawaratani, Norihisa Nishimura, Soichi Takeda, Hiroyuki Masuda, Akihiko Shibamoto, Takashi Inoue, Satoshi Iwai, Fumimasa Tomooka, Yuki Tsuji, Yukihisa Fujin
    Digestive Diseases and Sciences.2024; 69(3): 851.     CrossRef
  • Evaluation of Kidney Injury Using Arterial Spin Labeling and Blood Oxygen Level‐Dependent MRI: An Experimental Study in Rats With Carbon Tetrachloride‐Induced Liver Cirrhosis
    Jiaming Qin, Shuangshuang Xie, Yongquan Yu, Jiaqi Yang, Yumeng Zhao, Caixin Qiu, Xiaotian Li, Cheng Zhang, Zhandong Hu, Dan Tong, Jinxia Zhu, Bernd Kuehn, Wen Shen
    Journal of Magnetic Resonance Imaging.2024;[Epub]     CrossRef
  • Features of the course of hepatorenal syndrome in decompensated portal hypertension (case report)
    M.I. Tutchenko, D.V. Rudyk, M.S. Besedinskyi, S.L. Chub, Yu.V. Nerushchenko
    GASTROENTEROLOGY.2024; 58(2): 151.     CrossRef
  • Development and validation of a web-based nomogram for acute kidney injury in acute non-variceal upper gastrointestinal bleeding patients
    Chaolian Wei, Honghua Cao, Lina Huang, Lu-Huai Feng
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Can Novel Biomarkers Effectively Predict Acute Kidney Injury in Liver or Kidney Transplant Recipients?
    Hubert Zywno, Wojciech Figiel, Michal Grat, Slawomir Nazarewski, Zbigniew Galazka, Jolanta Malyszko
    International Journal of Molecular Sciences.2024; 25(22): 12072.     CrossRef
  • Novel biomarkers of acute kidney injury in chronic liver disease: Where do we stand after a decade of research?
    Rohan Vijay Yewale, Balakrishnan Siddartha Ramakrishna
    Hepatology Research.2023; 53(1): 3.     CrossRef
  • Medication dosing in adult patients with reduced lean body mass and kidney injury: A focus on cystatin C
    Brian L Erstad, David E Nix
    American Journal of Health-System Pharmacy.2023; 80(12): 712.     CrossRef
  • Acute kidney injury in patients with acute-on-chronic liver failure: clinical significance and management
    Jeong-Ju Yoo, Moo Yong Park, Sang Gyune Kim
    Kidney Research and Clinical Practice.2023; 42(3): 286.     CrossRef
  • Urinary N-Acetyl-Beta-D-Glucosaminidase levels predict immunoglobulin a nephropathy remission status
    Xiao Liu, Shaomin Gong, Yichun Ning, Yang Li, Huili Zhou, Luna He, Lin Lin, Shi Jin, Ziyan Shen, Bowen Zhu, Fang Li, Jie Li, Xiao Tan, Xiaoyan Jiao, Yiqin Shi, Xiaoqiang Ding
    BMC Nephrology.2023;[Epub]     CrossRef
  • Hepatorenal syndrome: Current concepts and future perspectives
    Chan-Young Jung, Jai Won Chang
    Clinical and Molecular Hepatology.2023; 29(4): 891.     CrossRef
  • Diagnostic value of combined detection of urine NGAL, KIM-1, and TFF3 in acute tubular necrosis associated with cirrhosis
    Yan-Qing Gong, Ying Zhao, Yan-Hui Jia, Man Li, Yong Jiang
    World Chinese Journal of Digestology.2023; 31(19): 808.     CrossRef
  • Influence of fluid balance on postoperative outcomes after hepatic resection in patients with left ventricular diastolic dysfunction
    Jungho Shin, Suk-Won Suh
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Urinary neutrophil gelatinase-associated lipocalin: Acute kidney injury in liver cirrhosis
    Pooja Basthi Mohan, Shankar Prasad Nagaraju, Dharshan Rangaswamy, Balaji Musunuri, Ravindra Prabhu Attur, Ganesh Bhat, Shailesh, Shiran Shetty
    Clinica Chimica Acta.2021; 523: 339.     CrossRef
  • 13,114 View
  • 375 Download
  • 25 Web of Science
  • Crossref

Viral hepatitis

Extrahepatic manifestations of hepatitis E virus: An overview
Fotios S. Fousekis, Ioannis V. Mitselos, Dimitrios K. Christodoulou
Clin Mol Hepatol 2020;26(1):16-23.
Published online October 11, 2019
DOI: https://doi.org/10.3350/cmh.2019.0082
Hepatitis E virus (HEV) is a significant health problem with approximately 20 million individuals infected annually. HEV infection has been associated with a wide spectrum of extrahepatic manifestations, including neurological, hematological and renal disorders. Guillain-Barré syndrome and neuralgic amyotrophy are the most frequent neurological manifestations. In addition, HEV infection has been observed with other neurological diseases, such as encephalitis, myelitis and Bell’s palsy. Hematologic manifestations include anemia due to glucose-6-phospate dehydrogonase deficiency, autoimmune hemolytic anemia and severe thrombocytopenia. Membranoproliferative glomerulonephritis and relapse IgA nephropathy with or without coexisting cryoglobulinemia appear to be the most common renal injuries related with HEV infection. Also, HEV infection has been associated with acute pancreatitis and other immune-mediated manifestations, such as arthritis and myocarditis. However, the pathophysiologic mechanisms of HEV-related extrahepatic manifestations are still largely unclear.

Citations

Citations to this article as recorded by  Crossref logo
  • Hepatitis A to E in People with HIV: A Virus-Specific Review of Prevention and Treatment
    Kuan-Yin Lin, Yi-Chia Huang, Miao-Hui Huang, Tsung-Yu Tsai, Guan-Jhou Chen, Yu-Shan Huang, Sung-Hsi Huang, Hsin-Yun Sun, Chien-Ching Hung
    Infectious Diseases and Therapy.2026; 15(2): 391.     CrossRef
  • Detection of Rocahepevirus ratti in Bivalve Mollusks from São Luís Island, Maranhão, Brazil: A Potential Transmission Route of an Emerging Zoonotic Pathogen?
    Andreza Soriano Figueiredo, Isabella Rodrigues Negreiros, Aldaleia do Nascimento e Silva, Caroline Roberta Soares Salgado, Natália Lourenço dos Santos, Marcelo Alves Pinto, Alcina Vieira de Carvalho Neta, José Paulo Gagliardi Leite, Carina Pacheco Cantell
    Food and Environmental Virology.2025;[Epub]     CrossRef
  • Rapid visual detection of hepatitis E virus combining reverse transcription recombinase-aided amplification with lateral flow dipstick and real-time fluorescence
    Bingyan Wei, Wenlong Wang, Zixuan Guo, Wenjiao Yin, Minheng Cheng, Yifei Yang, Yuewei Tian, Yaxin Sun, Tianlong Liu, Yanxin Hu, Ruiping She, Jijing Tian, Barbara A. Byrne
    Journal of Clinical Microbiology.2025;[Epub]     CrossRef
  • Utility of hypervariable region in hepatitis E virus for genetic evolution analysis and epidemiological studies
    Dong-Hwi Kim, Da-Yoon Kim, Jae-Hyeong Kim, Kyu-Beom Lim, Andrew Y. Cho, Joong-Bok Lee, Seung-Yong Park, Chang-Seon Song, Sang-Won Lee, Dong-Hun Lee, Do-Geun Kim, In-Soo Choi
    Journal of General Virology .2025;[Epub]     CrossRef
  • Heterogeneity in the seroprevalence of hepatitis E virus among hospital attendees: a retrospective study in Shanghai, China
    Jie Lu, Qing Li, Chenxi Zhang, Ziqiang Li, Qing Guo, Zhujun Cao, Yu-Feng Yao, Qing Xie
    Infectious Diseases.2025; 57(7): 647.     CrossRef
  • Hepatitis E Virus in the Role of an Emerging Food-Borne Pathogen
    Alica Pavlova, Bozena Kocikova, Michaela Urda Dolinska, Anna Jackova
    Microorganisms.2025; 13(4): 885.     CrossRef
  • Neurological Manifestations of HEV Infection: A Rare Phenomenon or an Underrecognized Reality?
    Maider Iza, Daniel Ramos, Arnau Llauradó, Juan Luis Restrepo‐Vera, Mercedes Pallero, Galo Granados, Jose Alemany, Javier Sotoca, Júlia Sampol, Sergi Martí, Daniel Sanchez‐Tejerina, Maria Salvadó, Raul Juntas
    Brain and Behavior.2025;[Epub]     CrossRef
  • High Seroprevalence of Hepatitis E Virus Among Patients With Hepatitis B and Those With Hepatitis of Unknown Etiology in Central Vietnam
    Le Chi Cao, Tran Thi Tien Xinh, Taanvi Gowdar, Dang Ngoc Phuoc, Nguyen Thi Dung, Tran Thi Kim Loan, Pham Van Duc, Dao Thi Huyen, Le Thi Kieu Linh, Le Huu Song, Thirumalaisamy P Velavan
    Open Forum Infectious Diseases.2025;[Epub]     CrossRef
  • Differential miRNA signatures in Hepatitis E Virus Infection: Insights into acute, chronic, and pregnancy-related outcomes
    Nancy León-Janampa, Julien Marlet
    European Journal of Clinical Microbiology & Infectious Diseases.2025; 44(10): 2303.     CrossRef
  • Cell line-dependent release of quasi-enveloped hepatitis E virus reveals alternative Golgi-associated egress in the absence of pORF3
    Nele Gremmel, Mirco Glitscher, Johannes Scholz, Ashish Gadicherla, Reimar Johne, Eberhard Hildt, Paul Becher
    Frontiers in Cellular and Infection Microbiology.2025;[Epub]     CrossRef
  • Chronic hepatitis E: The neglected liver killer
    Chang-Yi Ji, Meng-Meng Gu, Lan Huang, Jian Wu, Hong-Tao Wang
    Hepatobiliary & Pancreatic Diseases International.2025; 24(6): 607.     CrossRef
  • Update on Hepatitis E Virus Infection 2025: Insights From an International Symposium
    Lara Buchardt, Viet Loan Dao Thi, Reimar Johne, Mathias Ziersch, Dominik Harms, Jörg Hofmann, Katja Dinkelborg, Mara Klöhn, Mira Choi, Jens Kurreck, Heiner Wedemeyer, Daniel Todt
    Liver International.2025;[Epub]     CrossRef
  • SCREENING FOR HEPATITIS E VIRUS IN BLOOD DONORS IN NORTH MACEDONIA
    Marija Tashkovska, Tatjana Makarovska Bojadjieva, Elena Ristovska, Ivana Babalj Veljanoski, Aleksandra Stojchevska
    Academic Medical Journal.2025; 5(3): 68.     CrossRef
  • Neurological manifestation of HEV infection: still a rare disease entity?
    Maximilian Wiesenfarth, Thomas Stamminger, Eugen Zizer, Hayrettin Tumani, Albert C. Ludolph
    Journal of Neurology.2024; 271(1): 386.     CrossRef
  • Acute Hepatitis E Virus Infection Triggering Autoimmune Hepatitis in a Patient With Chronic Liver Disease: Case Report and the Review of the Literature
    Sayan Malakar, Nishant Shah, Ankit Mishra, Vipin Pandey, Vivek V Shirol, Naganath K Wodeyar, Prabhat Verma, Sai Prathap, Kartik Balankhe, Ramnawal Rao, Uday C Ghoshal
    Cureus.2024;[Epub]     CrossRef
  • Hepatitis E associated determinants and diagnostic biomarkers during pregnancy and its prenatal consequences in Multan, Punjab tertiary care setting (Pakistan)
    Ambreen Aisha
    American Journal of Translational Research.2024; 16(5): 2049.     CrossRef
  • Testing Hepatitis E Seroprevalence among HIV-Infected Patients in Greece: The SHIP Study
    Nikolina Antonopoulou, Georgios Schinas, Zoi Kotsiri, Olga Tsachouridou, Konstantinos Protopapas, Vasileios Petrakis, Emmanouil C. Petrakis, Despoina Papageorgiou, Dimosthenis Tzimotoudis, Simeon Metallidis, Antonios Papadopoulos, Markos Marangos, Emmanou
    Pathogens.2024; 13(7): 536.     CrossRef
  • Research Progress of Anemia Degree in Predicting the Prognosis of Infectious Diseases
    林 韩
    Advances in Clinical Medicine.2024; 14(07): 682.     CrossRef
  • Characterization of zoonotic hepatitis E virus in domestic pigs and wild boar in Vietnam: Implications for public health
    Le Chi Cao, Le Nguyen Nhat Ha, Tran Thi Giang, Vo Minh Tiep, Ngo Thi Minh Chau, Ton Nu Phuong Anh, Pham Khanh Duy, Le Phuc Nhan, Nguyen Thi Thu Hoai, Le Thi Kieu Linh, Nourhane Hafza, C. Thomas Bock, Truong Nhat My, Bui Tien Sy, Nguyen Linh Toan, Le Huu S
    One Health.2024; 19: 100857.     CrossRef
  • Investigating the Hepatitis E Virus (HEV) Diversity in Rat Reservoirs from Northern Italy
    Luca De Sabato, Marina Monini, Roberta Galuppi, Filippo Maria Dini, Giovanni Ianiro, Gabriele Vaccari, Fabio Ostanello, Ilaria Di Bartolo
    Pathogens.2024; 13(8): 633.     CrossRef
  • From discovery to treatment: tracing the path of hepatitis E virus
    Arash Letafati, Zahra Taghiabadi, Mahshid Roushanzamir, Bahar Memarpour, Saba Seyedi, Ali Vasheghani Farahani, Masoomeh Norouzi, Saeideh Karamian, Arghavan Zebardast, Marzieh Mehrabinia, Omid Salahi Ardekani, Tina Fallah, Fatemeh Khazry, Samin Fathi Danes
    Virology Journal.2024;[Epub]     CrossRef
  • Increasing trends in hepatitis E hospitalisations in Spain, 1997 to 2019
    María Guerrero-Vadillo, Marina Peñuelas, Rocío Carmona, Inmaculada León-Gómez, Carmen Varela
    Eurosurveillance.2024;[Epub]     CrossRef
  • Acute Viral Hepatitis E Presenting With Bell’s Palsy and Acute Pancreatitis: A Case Report
    Sayan Malakar, Sanjit Kumar, Sumit Rungta, Srikanth Kothalkar, Arvind Kumar, Krishna P Kohli, Rahul Jangra, Gaya P Shukla, Mayank Agarwal, Dheeraj Yadav, Anubhav Parwar, Saurabh Mishra, Akriti Bhardwaj
    Cureus.2024;[Epub]     CrossRef
  • Transverse myelitis associated in young patient with hepatitis e: a rare neurological complication
    Dr. Amina Saddiqa, Dr. Usama Hayyan, Dr. Muhammad Annas Farooq, Dr. Haris Majid Rajput, Dr. Zeeshan Munawar, Dr. Mazhar Badshah
    Journal of Neurology & Stroke.2024; 14(6): 198.     CrossRef
  • EXTRAHEPATIC MANIFESTATIONS IN PATIENTS WITH ACUTE HEPATITIS E – PAZARDZHIK, BULGARIA 2014 – 2022
    Maria Pishmisheva-Peleva, Stanislav Kotsev, Elitsa Golkocheva-Markova, Radka Argirova
    PROBLEMS of Infectious and Parasitic Diseases.2024; 52(2): 5.     CrossRef
  • Hepatitis E Virus Seroprevalence Indicated a Significantly Increased Risk Selectively in Patients with Gastric Cancer among 17 Common Malignancies
    Xiaona Lin, Ming Luo, Qiuxiong Lin, Juan Zhang, Teng Li, Xiaoyong Pu, Keping Xie, Jun Hou, Ren Chen
    Journal of Clinical Medicine.2023; 12(2): 437.     CrossRef
  • Specific Plasma MicroRNA Signatures Underlying the Clinical Outcomes of Hepatitis E Virus Infection
    Maria I. Costafreda, Silvia Sauleda, Mar Riveiro-Barciela, Angie Rico, Meritxell Llorens-Revull, Susana Guix, Rosa M. Pintó, Albert Bosch, Francisco Rodríguez-Frías, Ariadna Rando, Maria Piron, Marta Bes, Meghan Starolis
    Microbiology Spectrum.2023;[Epub]     CrossRef
  • Age and Gender Trends in the Prevalence of Markers for Hepatitis E Virus Exposure in the Heterogeneous Bulgarian Population
    Elitsa Golkocheva-Markova, Chiydem Ismailova, Ani Kevorkyan, Ralitsa Raycheva, Sashka Zhelyazkova, Stanislav Kotsev, Maria Pishmisheva, Vanya Rangelova, Asya Stoyanova, Viliana Yoncheva, Tencho Tenev, Teodora Gladnishka, Iva Trifonova, Iva Christova, Roum
    Life.2023; 13(6): 1345.     CrossRef
  • Hepatitis E Virus Infections: Epidemiology, Genetic Diversity, and Clinical Considerations
    Busara Songtanin, Adebayo J. Molehin, Kevin Brittan, Wuttiporn Manatsathit, Kenneth Nugent
    Viruses.2023; 15(6): 1389.     CrossRef
  • The Re-Emergence of Hepatitis E Virus in Europe and Vaccine Development
    Gergana Zahmanova, Katerina Takova, Valeria Tonova, Tsvetoslav Koynarski, Laura L. Lukov, Ivan Minkov, Maria Pishmisheva, Stanislav Kotsev, Ilia Tsachev, Magdalena Baymakova, Anton P. Andonov
    Viruses.2023; 15(7): 1558.     CrossRef
  • Discovery of Hepatitis E and Its Impact on Global Health: A Journey of 44 Years about an Incredible Human-Interest Story
    Mohammad Sultan Khuroo
    Viruses.2023; 15(8): 1745.     CrossRef
  • Hepatitis E virus: a pathogen of rising significance
    Eva Pernicová
    Medicína pro praxi.2023; 20(2): 94.     CrossRef
  • Viral Biology and Immune Privilege in the Development of Extrahepatic Manifestations During Hepatitis E Virus Infection
    Javier Orozco-Cordoba, Camila Mazas, Gisela Du Pont, Edmundo Lamoyi, Graciela Cárdenas, Nora A. Fierro
    Viral Immunology.2023; 36(10): 627.     CrossRef
  • Hepatitis E virus and Bell’s palsy
    Miriam Fritz‐Weltin, Lisa Niedermeier, Estelle Frommherz, Nora Isenmann, Benedikt Csernalabics, Tobias Boettler, Christoph Neumann‐Haefelin, Dominique Endres, Marcus Panning, Benjamin Berger
    European Journal of Neurology.2022; 29(3): 820.     CrossRef
  • Transfusion-transmitted hepatitis E: What we know so far?
    Carmen Ka Man Cheung, Sunny Hei Wong, Alvin Wing Hin Law, Man Fai Law
    World Journal of Gastroenterology.2022; 28(1): 47.     CrossRef
  • Rhabdomyolyse avec tétraparésie secondaire à une hépatite virale E chez un patient sous statines
    B. Hanotte, J.B. Gaultier, F. Abravanel, B. Pozzetto, L. Féasson, P. Cathébras
    La Revue de Médecine Interne.2022; 43(4): 252.     CrossRef
  • Hepatitis E in immunocompromised individuals
    Konstantinos Damiris, Mohamad Aghaie Meybodi, Mumtaz Niazi, Nikolaos Pyrsopoulos
    World Journal of Hepatology.2022; 14(3): 482.     CrossRef
  • Acute Myocarditis Induced by Hepatitis E: An Uncommon Association
    Héloïse Emeriaud, Fabien Huet, François Roubille, Jean-Luc Pasquié
    CJC Open.2022; 4(8): 729.     CrossRef
  • Antiviral Activity of Zinc Oxide Nanoparticles and Tetrapods Against the Hepatitis E and Hepatitis C Viruses
    Jyoti Gupta, Minnah Irfan, Niranjan Ramgir, K. P. Muthe, A. K. Debnath, Shabnam Ansari, Jaya Gandhi, C. T. Ranjith-Kumar, Milan Surjit
    Frontiers in Microbiology.2022;[Epub]     CrossRef
  • Viral hepatitis: A narrative review of hepatitis A–E
    Zunirah Ahmed, Akshay Shetty, David W Victor, Sudha Kodali
    World Journal of Meta-Analysis.2022; 10(3): 99.     CrossRef
  • A ribavirin-induced ORF2 single-nucleotide variant produces defective hepatitis E virus particles with immune decoy function
    Toni Luise Meister, Yannick Brüggemann, Maximilian K. Nocke, Rainer G. Ulrich, Jonas Schuhenn, Kathrin Sutter, André Gömer, Verian Bader, Konstanze F. Winklhofer, Ruth Broering, Lieven Verhoye, Philip Meuleman, Florian W. R. Vondran, Charline Camuzet, Lau
    Proceedings of the National Academy of Sciences.2022;[Epub]     CrossRef
  • Micro RNAs—The Small Big Players in Hepatitis E Virus Infection: A Comprehensive Review
    Elitsa Golkocheva-Markova
    Biomolecules.2022; 12(11): 1543.     CrossRef
  • Promoting development of tertiary hospital by satisfaction surveys
    Jinyong Wang, Yu Wang, Baocheng Deng
    Community Acquired Infection.2022; 9: 7.     CrossRef
  • Towards the Improved Accuracy of Hepatitis E Diagnosis in Vulnerable and Target Groups: A Global Perspective on the Current State of Knowledge and the Implications for Practice
    Jasminka Talapko, Tomislav Meštrović, Emina Pustijanac, Ivana Škrlec
    Healthcare.2021; 9(2): 133.     CrossRef
  • Hepatitis E Virus Infection—Immune Responses to an Underestimated Global Threat
    Paul Kupke, Jens M. Werner
    Cells.2021; 10(9): 2281.     CrossRef
  • Deep Insight Into Long Non-coding RNA and mRNA Transcriptome Profiling in HepG2 Cells Expressing Genotype IV Swine Hepatitis E Virus ORF3
    Hanwei Jiao, Xuehong Shuai, Yichen Luo, Zhixiong Zhou, Yu Zhao, Bowen Li, Guojing Gu, Wenjie Li, Mengjuan Li, Hui Zeng, Xiaoyi Guo, Yu Xiao, Zhenhui Song, Ling Gan, Qingzhou Huang
    Frontiers in Veterinary Science.2021;[Epub]     CrossRef
  • Mechanism of Cross-Species Transmission, Adaptive Evolution and Pathogenesis of Hepatitis E Virus
    Putu Prathiwi Primadharsini, Shigeo Nagashima, Hiroaki Okamoto
    Viruses.2021; 13(5): 909.     CrossRef
  • Immune disorders and rheumatologic manifestations of viral hepatitis
    Roman Maslennikov, Vladimir Ivashkin, Irina Efremova, Elena Shirokova
    World Journal of Gastroenterology.2021; 27(18): 2073.     CrossRef
  • Zur Bedeutung des Blutspenderscreenings
    Jürgen Wenzel, Lutz Gürtler
    Trillium Diagnostik.2021; 19(2): 106.     CrossRef
  • Hepatitis E: Genotypes, strategies to prevent and manage, and the existing knowledge gaps
    Lubna Kamani, Zahra Ali Padhani, Jai K Das
    JGH Open.2021; 5(10): 1127.     CrossRef
  • HEV-Associated Neuralgic Amyotrophy: A Multicentric Case Series
    Johannes H. Bannasch, Benjamin Berger, Claus-Peter Schwartkop, Marco Berning, Oliver Goetze, Marcus Panning, Miriam Fritz-Weltin, George Trendelenburg, Mathias Gelderblom, Marc Lütgehetmann, Fridrike Stute, Thomas Horvatits, Meike Dirks, Christoph Antoni,
    Pathogens.2021; 10(6): 672.     CrossRef
  • Hepatitis E virus infection in a patient with alcohol related chronic liver disease: a case report of acute-on-chronic liver failure
    Anabella Fantilli, Sarah Daniela López Villa, Alina Zerega, Guadalupe Di Cola, Luis López, Maribel Wassaf Martínez, María Belén Pisano, Viviana Elizabeth Ré
    Virology Journal.2021;[Epub]     CrossRef
  • Seroprevalence of hepatitis E virus among different age groups in Tehran, Iran
    S. Sharifipour, K. Davoodi Rad
    New Microbes and New Infections.2020; 34: 100638.     CrossRef
  • Clinical cases of Hepatitis E in children
    O. S. Pozdeeva, O. G. Mokhova, M. N. Kankasova
    CHILDREN INFECTIONS.2020; 19(1): 64.     CrossRef
  • Characteristics of cases of hepatitis E in 2019 in Gunma prefecture: a small epidemic caused by the same subgenotype 3a strain
    Yuichi Yamazaki, Daisuke Uehara, Yuki Kanayama, Takayoshi Suga, Takashi Ueno, Takeshi Hatanaka, Satoshi Takakusagi, Hiroki Tojima, Daichi Takizawa, Atsushi Naganuma, Takashi Kosone, Hiroaki Nakajima, Ken Sato, Satoru Kakizaki, Hitoshi Takagi, Toshio Uraok
    Kanzo.2020; 61(9): 478.     CrossRef
  • Viral Hepatitis E and Chronicity: A Growing Public Health Concern
    Vikram Thakur, Radha Kanta Ratho, Swatantra Kumar, Shailendra K. Saxena, Ishani Bora, Pryanka Thakur
    Frontiers in Microbiology.2020;[Epub]     CrossRef
  • Fulminant Hepatic Failure in Glucose-6-Phosphate Dehydrogenase (G6PD) Deficient Patients Caused by Hepatitis E Infection: A Single Disease With Different Spectrums
    Lubna Kamani, Hafeezullah Shaikh, Ajit Kumar Khemchandani
    Cureus.2020;[Epub]     CrossRef
  • 15,997 View
  • 427 Download
  • 55 Web of Science
  • Crossref

Original Article

Viral hepatitis

Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals
Alessio Strazzulla, Giuseppe Coppolino, Giorgio Settimo Barreca, Innocenza Gentile, Laura Rivoli, Maria Concetta Postorino, Maria Mazzitelli, Giuseppe Greco, Chiara Costa, Vincenzo Pisani, Nadia Marascio, Mariadelina Simeoni, Alfredo Focà, Giorgio Fuiano, Daniela Foti, Elio Gulletta, Carlo Torti
Clin Mol Hepatol 2018;24(2):151-162.
Published online April 24, 2018
DOI: https://doi.org/10.3350/cmh.2017.0059
Background/Aims
Correct renal function evaluation is based on estimated glomerular filtration rates (eGFR) and complementary renal damage biomarkers, such as neutrophil gelatinase associated lipocalin (NGAL). The aim of this study was to evaluate eGFR and NGAL modifications and renal impairment during treatment with a direct acting antiviral (DAA) for chronic hepatitis C virus (HCV) infection.
Methods
A retrospective cohort study evaluated eGFR modification during treatment with DAA. Subgroup analysis on serum NGAL was conducted in those receiving sofosbuvir/ledipasvir, with complete follow-up until week 12 after the end of treatment (FU-12).
Results
In the 102 enrolled patients, eGFR reduction was observed (from 86.22 mL/min at baseline to 84.43 mL/min at FU-12, P=0.049). Mean NGAL increased in 18 patients (from 121.89 ng/mL at baseline to 204.13 ng/mL at FU-12, P=0.014). At FU-12, 38.8% (7/18) of patients had a plasmatic NGAL value higher than the normal range (36-203 ng/mL) compared with 11.1% (2/18) at baseline (χ 2 =3,704; P=0.054). In contrast, eGFR did not change significantly over the follow-up in this subgroup.
Conclusions
In conclusion, compared to a negligible eGFR decline observed in the entire cohort analyzed, a significant NGAL increase was observed after HCV treatment with DAA in a small subgroup. This could reflect tubular damage during DAA treatment rather than glomerular injury.

Citations

Citations to this article as recorded by  Crossref logo
  • Dynamic changes and clinical value of lipocalin 2 in liver diseases caused by microbial infections
    Feng Chen, Shan-Shan Wu, Chao Chen, Cheng Zhou
    World Journal of Hepatology.2024; 16(2): 177.     CrossRef
  • Evaluating short-term and long-term liver fibrosis improvement in hepatitis C patients after DAA treatment
    Yifan Wang, Xinyan Ma, Yanzheng Zou, Ming Yue, Meiling Zhang, Rongbin Yu, Hongbo Chen, Peng Huang
    The Journal of Biomedical Research.2024; 38(5): 464.     CrossRef
  • Stem Cells in Kidney Ischemia: From Inflammation and Fibrosis to Renal Tissue Regeneration
    Rosario Cianci, Mariadelina Simeoni, Eleonora Cianci, Oriana De Marco, Antonio Pisani, Claudio Ferri, Antonietta Gigante
    International Journal of Molecular Sciences.2023; 24(5): 4631.     CrossRef
  • Renal Stem Cells, Renal Resistive Index, and Neutrophil Gelatinase Associated Lipocalin Changes After Revascularization in Patients With Renovascular Hypertension and Ischemic Nephropathy
    Rosario Cianci, Mariadelina Simeoni, Antonietta Gigante, Adolfo Marco Perrotta, Sonia Ronchey, Nicola Mangialardi, Annalisa Schioppa, Oriana De Marco, Eleonora Cianci, Cristiana Barbati, Silvia Lai, Claudio Ferri
    Current Pharmaceutical Design.2023; 29(2): 133.     CrossRef
  • Impact of Thyroid Cancer Treatment on Renal Function: A Relevant Issue to Be Addressed
    Rossella Di Paola, Ananya De, Anna Capasso, Sofia Giuliana, Roberta Ranieri, Carolina Ruosi, Antonella Sciarra, Caterina Vitagliano, Alessandra F. Perna, Giovambattista Capasso, Mariadelina Simeoni
    Journal of Personalized Medicine.2023; 13(5): 813.     CrossRef
  • INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease
    Anil Arora, Ashish Kumar, Narayan Prasad, Ajay Duseja, Subrat K. Acharya, Sanjay K. Agarwal, Rakesh Aggarwal, Anil C. Anand, Anil K. Bhalla, Narendra S. Choudhary, Yogesh K. Chawla, Radha K. Dhiman, Vinod K. Dixit, Natarajan Gopalakrishnan, Ashwani Gupta,
    Journal of Clinical and Experimental Hepatology.2021; 11(3): 354.     CrossRef
  • HCV cirrhotic patients treated with direct‐acting antivirals: Detection of tubular dysfunction and resolution after viral clearance
    Elisa Biliotti, Donatella Palazzo, Francesca Tinti, Maria Domenica D'Alessandro, Rozenn Esvan, Raffaella Labriola, Andrea Cappoli, Ilaria Umbro, Lorenzo Volpicelli, Alessandra Bachetoni, Erica Villa, Anna Paola Mitterhofer, Paola Rucci, Gloria Taliani
    Liver International.2021; 41(1): 158.     CrossRef
  • Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals
    Yen-Chun Chen, Chen-Hao Li, Ping-Hung Ko, Chi-Che Lee, Ru-Jiang Syu, Chih-Wei Tseng, Kuo-Chih Tseng, Chen-Hua Liu
    PLOS ONE.2021; 16(8): e0256505.     CrossRef
  • Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents
    Tyng‐Yuan Jang, Ching‐I Huang, Ming‐Lun Yeh, Po‐Cheng Liang, Pei‐Chien Tsai, Yi‐Hung Lin, Ming‐Yen Hsieh, Nai‐Jen Hou, Zu‐Yau Lin, Shinn‐Cherng Chen, Jee‐Fu Huang, Chia‐Yen Dai, Chung‐Feng Huang, Wan‐Long Chuang, Ming‐Lung Yu
    Journal of Gastroenterology and Hepatology.2020; 35(3): 473.     CrossRef
  • Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir
    Ali Nada, Mohamed Abbasy, Aliaa Sabry, Azza Mohamed Abdu Allah, Somaia Shehab-Eldeen, Nada Elnaidany, Hanan Elimam, Kawthar Ibraheem Mohamed Ibraheem, Abdallah Essa
    Canadian Journal of Gastroenterology and Hepatology.2020; 2020: 1.     CrossRef
  • Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy)
    Vincenzo Scaglione, Maria Mazzitelli, Chiara Costa, Vincenzo Pisani, Giuseppe Greco, Francesca Serapide, Rosaria Lionello, Valentina La Gamba, Nadia Marascio, Enrico Maria Trecarichi, Carlo Torti
    Medicina.2020; 56(3): 101.     CrossRef
  • Looking beyond Entecavir to discover Gitelman Syndrome in a 50 year-old man
    M Simeoni, V Columbano, Y Suzumoto, L Salviano, G Capolongo, M Zacchia, F Del Vecchio Blanco, A F Perna, V Nigro, G Capasso, F Trepiccione
    QJM: An International Journal of Medicine.2020; 113(10): 739.     CrossRef
  • Hepatitis C virus and the kidney
    Stanislas Pol, Lucia Parlati, Michel Jadoul
    Nature Reviews Nephrology.2019; 15(2): 73.     CrossRef
  • 9,821 View
  • 123 Download
  • 15 Web of Science
  • Crossref

Editorial

Viral hepatitis

Use of sofosbuvir in chronic kidney disease: Is it necessary?
Tae Seop Lim, Sang Hoon Ahn
Clin Mol Hepatol 2017;23(4):308-310.
Published online September 26, 2017
DOI: https://doi.org/10.3350/cmh.2017.0109

Citations

Citations to this article as recorded by  Crossref logo
  • Assessment of Renal Function in Egyptian HCV Patients Treated with Combination Therapy of Sofosbuvir and Daclatasvir
    Hala Abd El Maguid, Ahmed Heiba, Enass El Sayed, Hazem El-Hariri, Haythem Tolba, Muhammad Abdel Ghaffar
    Open Access Macedonian Journal of Medical Sciences.2022; 10(B): 82.     CrossRef
  • Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment
    Mark Sulkowski, Laura E. Telep, Massimo Colombo, Francois Durand, K. Rajender Reddy, Eric Lawitz, Marc Bourlière, Nelson Cheinquer, Stacey Scherbakovsky, Liyun Ni, Lindsey Force, Heribert Ramroth, Anuj Gaggar, Anand P. Chokkalingam, Meghan E. Sise
    Alimentary Pharmacology & Therapeutics.2022; 55(9): 1169.     CrossRef
  • Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir
    Ali Nada, Mohamed Abbasy, Aliaa Sabry, Azza Mohamed Abdu Allah, Somaia Shehab-Eldeen, Nada Elnaidany, Hanan Elimam, Kawthar Ibraheem Mohamed Ibraheem, Abdallah Essa
    Canadian Journal of Gastroenterology and Hepatology.2020; 2020: 1.     CrossRef
  • An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy
    Guglielmo Borgia, Riccardo Scotto, Antonio Riccardo Buonomo
    Expert Opinion on Investigational Drugs.2019; 28(5): 395.     CrossRef
  • Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection
    Riccardo Scotto, Antonio Riccardo Buonomo, Nicola Schiano Moriello, Alberto Enrico Maraolo, Emanuela Zappulo, Biagio Pinchera, Ivan Gentile, Guglielmo Borgia
    Reviews on Recent Clinical Trials.2019; 14(3): 173.     CrossRef
  • Lamivudine: fading into the mists of time
    Jonggi Choi, Young-Suk Lim
    Clinical and Molecular Hepatology.2017; 23(4): 314.     CrossRef
  • 8,979 View
  • 123 Download
  • 4 Web of Science
  • Crossref

Original Article

Viral hepatitis

Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
Hyun Phil Shin, Ji-Ae Park, Blaire Burman, Richard A. Kozarek, Asma Siddique
Clin Mol Hepatol 2017;23(4):316-322.
Published online August 22, 2017
DOI: https://doi.org/10.3350/cmh.2016.0087
Background/Aims
Treatment of chronic hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) is essential. The availability of sofosbuvir (SOF) has dramatically improved overall HCV cure rates, however there is insufficient data regarding its use in patients with CKD. We evaluated SOF in patients with hepatitis C genotype 1 (G1) and moderately impaired renal function.
Methods
We retrospectively reviewed all patients treated with a SOF-based regimen from December 2013 through September 2015 at Virginia Mason Medical Center. Data was then collected for HCV G1 patients with stage 3 CKD.
Results
A total of 28 patients with HCV G1 and stage 3 CKD were treated with a SOF-based regimen. Twenty-one patients had stage 3A CKD (estimated glomerular filtration rate [eGFR] 45–60 mL/min/1.73m2) and 7 patients had stage 3B CKD (eGFR 30–45 mL/min/1.73m2). The overall rate of sustained virologic response (SVR) 12 weeks after completion of therapy (SVR12) was 85.7% (24/28). SVR12 in stage 3A CKD patients was 81.0% (17/21) and in stage 3B CKD patients, SVR12 was 100% (7/7). Based on the treatment regimen used, the SVR12 was 81.8% (9/11), 92.3% (12/13), and 75.0% (3/4) for SOF/ledipasvir (LDV), SOF/simeprevir (SIM), and SOF/pegylated interferon (PEG)/ribavirin (RBV), respectively. Greater than 30% reduction eGFR was observed in 5 out of 28 patients.
Conclusions
SOF-based regimens resulted in high SVR12 rates in patients with moderately impaired renal function. During therapy, HCV patients with CKD should be carefully monitored for worsening renal function.

Citations

Citations to this article as recorded by  Crossref logo
  • Efficacy and safety of SOF/LDV in HCV-infected children and adolescents on hemodialysis: a prospective single-center observational study
    Afaf Enayet, Hanaa El-Karaksy, Engy Mogahed, Noha Yasin, Haytham Ghita, Yasmin Ramadan
    Pediatric Nephrology.2026;[Epub]     CrossRef
  • Assessment of Renal Function in Egyptian HCV Patients Treated with Combination Therapy of Sofosbuvir and Daclatasvir
    Hala Abd El Maguid, Ahmed Heiba, Enass El Sayed, Hazem El-Hariri, Haythem Tolba, Muhammad Abdel Ghaffar
    Open Access Macedonian Journal of Medical Sciences.2022; 10(B): 82.     CrossRef
  • Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis
    Jieun Lee, Sang Bong Ahn, Sun Young Yim, Jihyun An, Dae Won Jun, Min Jung Ko, Dong Ah Park, Jeong‐Ju Yoo
    Journal of Viral Hepatitis.2022; 29(7): 496.     CrossRef
  • Safety and Efficacy of Antiviral Therapy of Chronic Hepatitis C in Chronic Kidney Disease and Hemodialysis Patients
    W. Fadili, A. Ait Errami, S. Zaoui, K. Elkassimi, N. ElBouhi, S. Oubaha, Z. Samlani, I. Laouad, K. Krati
    European Journal of Medical and Health Sciences.2021; 3(1): 160.     CrossRef
  • Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease
    Ezequiel Ridruejo, Rebeca Garcia-Agudo, Manuel Mendizabal, Sami Aoufi-Rabih, Vivek Dixit, Marcelo Silva, Fabrizio Fabrizi
    Nefrología.2020; 40(1): 46.     CrossRef
  • Sofosbuvir‐containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment
    Rasha Eletreby, Magdy El‐Serafy, Mahmoud Anees, Gamal Kasem, Marwa Salama, Reham Elkhouly, Mostafa Hamdy, Hisham Abdel Haleem, Ehab Kamal, Wael Abdel‐Razek, Rabab Salama, Mohamed Elshenawy, Ayman Shafeek, Mohamed Hassany, Manal H. El‐Sayed, Yehia El‐Shazl
    Liver International.2020; 40(4): 797.     CrossRef
  • Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease
    Ezequiel Ridruejo, Rebeca Garcia-Agudo, Manuel Mendizabal, Sami Aoufi-Rabih, Vivek Dixit, Marcelo Silva, Fabrizio Fabrizi
    Nefrología (English Edition).2020; 40(1): 46.     CrossRef
  • Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment
    Shao-Ming Chiu, Ming-Chao Tsai, Chun-Yen Lin, Chien-Hung Chen, Sheng-Nan Lu, Chao-Hung Hung, I-Shyan Sheen, Rong-Nan Chien, Chih-Lang Lin, Tsung-Hui Hu, Yu-Fan Cheng, Chao-Long Chen, Tatsuo Kanda
    PLOS ONE.2020; 15(4): e0231102.     CrossRef
  • Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis
    Kazumichi Abe, Hiroto Wakabayashi, Haruo Nakayama, Tomohiro Suzuki, Masahito Kuroda, Naoe Yoshida, Jun Tojo, Atsuko Kogure, Tsuyoshi Rai, Hironobu Saito, Shinji Mukai, Masashi Fujita, Manabu Hayashi, Atsushi Takahashi, Hiromasa Ohira, Ming-Lung Yu
    PLOS ONE.2020; 15(12): e0243473.     CrossRef
  • Treating hepatitis C virus in dialysis patients: How, when, and why?
    Javier Pagan, Marco Ladino, David Roth
    Seminars in Dialysis.2019; 32(2): 152.     CrossRef
  • Sofosbuvir

    Reactions Weekly.2018; 1688(1): 219.     CrossRef
  • Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic
    Jessica L. Michal, Saira Rab, Manish Patel, Alison W. Kyle, Lesley S. Miller, Kirk A. Easley, Aley G. Kalapila
    AIDS Research and Human Retroviruses.2018; 34(8): 690.     CrossRef
  • Renal safety after one year of sofosbuvir‐based therapy for chronic hepatitis C: A Brazilian “real‐life” study
    T. Medeiros, N. F. Rosário, G. N. Saraiva, T. G. Andrade, A. A. Silva, J. R. Almeida
    Journal of Clinical Pharmacy and Therapeutics.2018; 43(5): 707.     CrossRef
  • 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

    Clinical and Molecular Hepatology.2018; 24(3): 169.     CrossRef
  • Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis
    Chih-Chin Kao, Yu-Shiuan Lin, Heng-Cheng Chu, Te-Chao Fang, Mai-Szu Wu, Yi-No Kang
    Journal of Clinical Medicine.2018; 7(10): 314.     CrossRef
  • Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir
    Josip Begovac, Juraj Krznarić, Nikolina Bogdanić, Loris Močibob, Šime Zekan
    Medicine.2018; 97(51): e13671.     CrossRef
  • Use of sofosbuvir in chronic kidney disease: Is it necessary?
    Tae Seop Lim, Sang Hoon Ahn
    Clinical and Molecular Hepatology.2017; 23(4): 308.     CrossRef
  • 11,182 View
  • 194 Download
  • 13 Web of Science
  • Crossref

Case Report

Viral hepatitis

Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases
Hyeki Cho, Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Kook-Hwan Oh, Kyoungbun Lee, Syifa Mustika, Jung-Hwan Yoon, Yoon Jun Kim
Clin Mol Hepatol 2016;22(2):286-291.
Published online June 25, 2016
DOI: https://doi.org/10.3350/cmh.2015.0066
Tenofovir disoproxil fumarate (TDF) is effective against chronic hepatitis B (CHB) infection and its use is increasing rapidly worldwide. However, it has been established that TDF is associated with renal toxicity in human immunodeficiency virus-infected patients, while severe or symptomatic TDF-associated nephrotoxicity has rarely been reported in patients with CHB. Here we present two patients with TDF-associated nephrotoxicity who were being treated for CHB infection. The first patient was found to have clinical manifestations of proximal renal tubular dysfunction and histopathologic evidence of acute tubular necrosis at 5 months after starting TDF treatment. The second patient developed acute kidney injury at 17 days after commencing TDF, and he was found to have membranoproliferative glomerulonephritis with acute tubular injury. The renal function improved in both patients after discontinuing TDF. We discuss the risk factors for TDF-associated renal toxicity and present recommendations for monitoring renal function during TDF therapy.

Citations

Citations to this article as recorded by  Crossref logo
  • Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection—General and Special Populations
    Lung‐Yi Mak, Tsung‐Hui Hu, Desmond Y. H. Yap
    Alimentary Pharmacology & Therapeutics.2026; 63(7): 945.     CrossRef
  • Urinary Levels of Neutrophil Gelatinase-associated Lipocalin and Cystatin C in Patients with Hepatitis B on Tenofovir Treatment
    Shivani Rani, Himanshu Dandu, Ambuj Yadav, Mahak Lamba, Amit Goel, Wahid Ali, Virendra Atam, Sumit Rungta, Medhavi Gautam, Atin Singhai
    Journal of The Association of Physicians of India.2025; 73(2): 13.     CrossRef
  • Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
    David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B
    Young Youn Cho, Young Chang, Joon Yeul Nam, Hyeki Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Gut and Liver.2020; 14(2): 225.     CrossRef
  • Entecavir and tenofovir on renal function in patients with hepatitis B virus‐related hepatocellular carcinoma
    Mi Young Jeon, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang‐Hyub Han, Sang Hoon Ahn, Seung Up Kim
    Journal of Viral Hepatitis.2020; 27(9): 932.     CrossRef
  • Editorial: tenofovir disoproxil fumarate vs entecavir in patients with chronic hepatitis B and renal impairment—still an open issue
    Sung Won Lee, Seung Up Kim
    Alimentary Pharmacology & Therapeutics.2020; 52(5): 889.     CrossRef
  • Tenofovir does not induce renal dysfunction compared to entecavir in post-liver-transplant hepatitis B virus patients
    Sang Jin Kim, Jinsoo Rhu, Seo Hee Lee, Jong Man Kim, Gyu-Seong Choi, Kyunga Kim, Jae-Won Joh
    Annals of Surgical Treatment and Research.2020; 99(3): 180.     CrossRef
  • A severe case of tenofovir-associated acute kidney injury requiring hemodialysis in a patient with chronic hepatitis B
    A Young Cho, Ju Hwan Oh, Hee-Chan Moon, Gum Mo Jung, Young Suk Lee, Yeong Jin Choi, In O Sun, Kwang Young Lee
    Kidney Research and Clinical Practice.2020; 39(3): 373.     CrossRef
  • Renal Dysfunction and Tubulopathy Induced by High-Dose Tenofovir Disoproxil Fumarate in C57BL/6 Mice
    Eungyeong Jang, Jong Kil Lee, Kyung-Soo Inn, Eun Kyoung Chung, Kyung-Tae Lee, Jang-Hoon Lee
    Healthcare.2020; 8(4): 417.     CrossRef
  • Application of High-Performance Liquid Chromatography for Simultaneous Determination of Tenofovir and Creatinine in Human Urine and Plasma Samples
    Patrycja Olejarz, Grażyna Chwatko, Paweł Kubalczyk, Krystian Purgat, Rafał Głowacki, Kamila Borowczyk
    Pharmaceuticals.2020; 13(11): 367.     CrossRef
  • Tenofovir-Associated Acute Kidney Disease: Is it Different in HIV- and HBV-Infected Patients?
    Fatemeh Ghasemi, Mohammadreza Salehi, Niloofar Khoshnam Rad, Hossein Khalili
    American Journal of Therapeutics.2019; 26(5): e639.     CrossRef
  • Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization
    Young Youn Cho, Young Hwan Choi, Su Jong Yu, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon
    Journal of Liver Cancer.2019; 19(2): 128.     CrossRef
  • Effect of tenofovir on renal function in patients with chronic hepatitis B
    Woo Jin Jung, Jae Young Jang, Won Young Park, Soung Won Jeong, Hee Jeong Lee, Sang Joon Park, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Suyeon Park, Baigal Baymbajav
    Medicine.2018; 97(7): e9756.     CrossRef
  • Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients
    H. J. Tsai, Y. W. Chuang, S. W. Lee, C. Y. Wu, H. Z. Yeh, T. Y. Lee
    Alimentary Pharmacology & Therapeutics.2018; 47(12): 1673.     CrossRef
  • Tenofovir disoproxil fumarate

    Reactions Weekly.2016; 1617(1): 214.     CrossRef
  • 16,135 View
  • 179 Download
  • 12 Web of Science
  • Crossref

Original Article

Liver fibrosis, cirrhosis, and portal hypertension

Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal
Yun Jung Choi, Jeong Han Kim, Ja Kyung Koo, Cho I Lee, Ji Young Lee, Jae Hoon Yang, Soon Young Ko, Won Hyeok Choe, So Young Kwon, Chang Hong Lee
Clin Mol Hepatol 2014;20(2):185-191.
Published online June 30, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.2.185
Background/Aims

A revised classification system for renal dysfunction in patients with cirrhosis was proposed by the Acute Dialysis Quality Initiative and the International Ascites Club Working Group in 2011. The aim of this study was to determine the prevalence of renal dysfunction according to the criteria in this proposal.

Methods

The medical records of cirrhotic patients who were admitted to Konkuk University Hospital between 2006 and 2010 were reviewed retrospectively. The data obtained at first admission were collected. Acute kidney injury (AKI) and chronic kidney disease (CKD) were defined using the proposed diagnostic criteria of kidney dysfunction in cirrhosis.

Results

Six hundred and forty-three patients were admitted, of whom 190 (29.5%), 273 (42.5%), and 180 (28.0%) were Child-Pugh class A, B, and C, respectively. Eighty-three patients (12.9%) were diagnosed with AKI, the most common cause for which was dehydration (30 patients). Three patients had hepatorenal syndrome type 1 and 26 patients had prerenal-type AKI caused by volume deficiency after variceal bleeding. In addition, 22 patients (3.4%) were diagnosed with CKD, 1 patient with hepatorenal syndrome type 2, and 3 patients (0.5%) with AKI on CKD.

Conclusions

Both AKI and CKD are common among hospitalized cirrhotic patients, and often occur simultaneously (16.8%). The most common type of renal dysfunction was AKI (12.9%). Diagnosis of type 2 hepatorenal syndrome remains difficult. A prospective cohort study is warranted to evaluate the clinical course in cirrhotic patients with renal dysfunction.

Citations

Citations to this article as recorded by  Crossref logo
  • Korean Society of Nephrology 2025 evidence-based clinical practice guideline for continuous kidney replacement therapy
    Jeonghwan Lee, Donghyuk Kang, Jin Hyuk Paek, Jangwook Lee, Jung Nam An, Junseok Jeon, Kyungho Lee, Hye Ryoun Jang, Jong Hyun Jhee, Hyo Jin Kim, Harin Rhee, Sung Yoon Lim, Jihyun Yang, Seong Geun Kim, Seung Seok Han, Shin Young Ahn, Sunghoon Park, Hyun Kyu
    Kidney Research and Clinical Practice.2026; 45(Suppl 1): S1.     CrossRef
  • Korean Society of Nephrology 2025 Evidence-Based Clinical Practice Guideline for Continuous Kidney Replacement Therapy
    Jeonghwan Lee, Donghyuk Kang, Jin Hyuk Paek, Jangwook Lee, Jung Nam An, Junseok Jeon, Kyungho Lee, Hye Ryoun Jang, Jong Hyun Jhee, Hyo Jin Kim, Harin Rhee, Sung Yoon Lim, Jihyun Yang, Seong Geun Kim, Seung Seok Han, Shin Young Ahn, Sunghoon Park, Hyun Kyu
    Electrolytes & Blood Pressure.2026; 24(1): 6.     CrossRef
  • Mortality of Acute Kidney Injury in Cirrhosis: A Systematic Review and Meta‐Analysis of Over 5 Million Patients Across Different Clinical Settings
    Vasileios Lekakis, Florence Wong, Aikaterini Gkoufa, George V. Papatheodoridis, Evangelos Cholongitas
    Alimentary Pharmacology & Therapeutics.2025; 61(3): 420.     CrossRef
  • A novel risk-predicted nomogram for acute kidney injury progression in decompensated cirrhosis: a double-center study in Vietnam
    Nghia N. Nguyen, Bao T. Nguyen, Thuy D. T. Nguyen, Tam T. T. Tran, Tan N. H. Mai, Huyen N. T. Le, Hoang N. Dang, Vy B. N. Nguyen, Nhi Y. T. Ngo, Cuong T. Vo
    International Urology and Nephrology.2025; 57(7): 2279.     CrossRef
  • Gynura procumbens leaf extract-loaded self-microemulsifying drug delivery system offers enhanced protective effects in the hepatorenal organs of the experimental rats
    Manik Chandra Shill, Md. Faisal Bin Jalal, Madhabi Lata Shuma, Patricia Prova Mollick, Md. Abdul Muhit, Shimul Halder, Miquel Vall-llosera Camps
    PLOS ONE.2025; 20(2): e0304435.     CrossRef
  • Biopharmaceutical characterization of Ajwain (Carum copticum) seed extract-loaded self-microemulsifying drug delivery system for enhanced hepatoprotective and nephroprotective activity
    Shimul Halder, Fatema-Tuz-Zohora, Tania Ahmed Chowdhury, Leon Bhowmik, Madhabi Lata Shuma, Harinarayan Das, Sulobh Sarkar, Md. Abdul Muhit, Manik Chandra Shill
    Scientific Reports.2025;[Epub]     CrossRef
  • Fibrotic Burden in Patients With Hepatitis B Virus–Related Cirrhosis Is Independently Associated With Poorer Kidney Outcomes
    Chan-Young Jung, Hui-Yun Jung, Hyung Woo Kim, Geun Woo Ryu, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    The Journal of Infectious Diseases.2024; 229(1): 108.     CrossRef
  • Study of prevalence, risk factors for acute kidney injury, and mortality in liver cirrhosis patients
    Pooja Basthi Mohan, Shankar Prasad Nagaraju, Balaji Musunuri, Siddheesh Rajpurohit, Ganesh Bhat, Shiran Shetty
    Irish Journal of Medical Science (1971 -).2024; 193(4): 1817.     CrossRef
  • Incidence and risk factors of acute kidney injury in cirrhosis: a systematic review and meta-analysis of 5,202,232 outpatients, inpatients, and ICU-admitted patients
    Vasileios Lekakis, Aikaterini Gkoufa, John Vlachogiannakos, George V. Papatheodoridis, Evangelos Cholongitas
    Expert Review of Gastroenterology & Hepatology.2024; 18(7): 377.     CrossRef
  • Acute kidney injury development and impact on clinical and economic outcomes in patients with cirrhosis: an observational cohort study over a 10-year period
    Osama Y. Alshogran, Shoroq M. Altawalbeh, Eman M. Almestarihi
    European Journal of Gastroenterology & Hepatology.2023; 35(4): 497.     CrossRef
  • Addition of Kidney Dysfunction Type to MELD-Na for the Prediction of Survival in Cirrhotic Patients Awaiting Liver Transplantation in Comparison with MELD 3.0 with Albumin
    Kyeong-Min Yeom, Jong-In Chang, Jeong-Ju Yoo, Ji Eun Moon, Dong Hyun Sinn, Young Seok Kim, Sang Gyune Kim
    Diagnostics.2023; 14(1): 39.     CrossRef
  • Acute Kidney Injury in Patients with Liver Cirrhosis: Prevalence, Predictors, and In‐Hospital Mortality at a District Hospital in Ghana
    Amoako Duah, Francisca Duah, Daniel Ampofo-Boobi, Bright Peprah Addo, Foster Osei-Poku, Adwoa Agyei-Nkansah, Maria Irene Bellini
    BioMed Research International.2022;[Epub]     CrossRef
  • Impact of acute kidney injury on the risk of mortality in patients with cirrhosis: a systematic review and meta-analysis
    Yunfeng Ning, Xiaoyue Zou, Jing Xu, Xiao Wang, Min Ding, Hulin Lu
    Renal Failure.2022; 44(1): 1934.     CrossRef
  • Keeping Patients with End-Stage Liver Disease Alive While Awaiting Transplant
    Andres F. Carrion, Paul Martin
    Clinics in Liver Disease.2021; 25(1): 103.     CrossRef
  • Chronic renal dysfunction in cirrhosis: A new frontier in hepatology
    Ramesh Kumar, Rajeev Nayan Priyadarshi, Utpal Anand
    World Journal of Gastroenterology.2021; 27(11): 990.     CrossRef
  • Predictors of Development of Hepatorenal Syndrome in Hospitalized Cirrhotic Patients with Acute Kidney Injury
    Roula Sasso, Ahmad Abou Yassine, Liliane Deeb
    Journal of Clinical Medicine.2021; 10(23): 5621.     CrossRef
  • Urinary neutrophil gelatinase-associated lipocalin: Acute kidney injury in liver cirrhosis
    Pooja Basthi Mohan, Shankar Prasad Nagaraju, Dharshan Rangaswamy, Balaji Musunuri, Ravindra Prabhu Attur, Ganesh Bhat, Shailesh, Shiran Shetty
    Clinica Chimica Acta.2021; 523: 339.     CrossRef
  • Acute kidney injury and hepatorenal syndrome in cirrhosis
    Kapil Gupta, Abhishek Bhurwal, Cindy Law, Scott Ventre, Carlos D Minacapelli, Savan Kabaria, You Li, Christopher Tait, Carolyn Catalano, Vinod K Rustgi
    World Journal of Gastroenterology.2021; 27(26): 3984.     CrossRef
  • Diagnosis and management of renal dysfunction in patients with cirrhosis
    Andres F. Carrion, Ramya Radhakrishnan, Paul Martin
    Expert Review of Gastroenterology & Hepatology.2020; 14(1): 1.     CrossRef
  • Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI?
    Zehao Tan, Wey Chyi Teoh, Kang Min Wong, Gervais Khin-Lin Wansaicheong, Kumaresan Sandrasegaran
    Clinical Imaging.2020; 62: 63.     CrossRef
  • Evaluation of Renal Disease in Patients With Cirrhosis
    Erik L. Lum, Piyavadee Homkrailas, Suphamai Bunnapradist
    Journal of Clinical Gastroenterology.2020; 54(4): 314.     CrossRef
  • Incidence, Mortality and Predictors of Acute Kidney Injury in Patients with Cirrhosis: A Systematic Review and Meta-analysis
    Raseen Tariq, Yousaf Hadi, Khusdeep Chahal, Sivani Reddy, Habeeb Salameh, Ashwani K. Singal
    Journal of Clinical and Translational Hepatology.2020; 8(2): 135.     CrossRef
  • Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma
    Paulo Henrique Lima, Boyan Fan, Joshua Bérubé, Milena Cerny, Damien Olivié, Jeanne-Marie Giard, Catherine Beauchemin, An Tang
    American Journal of Roentgenology.2019; 213(1): 17.     CrossRef
  • Impact of Chronic Kidney Disease on Outcomes in Cirrhosis
    Florence Wong, K. Rajender Reddy, Jacqueline G. O’Leary, Puneeta Tandon, Scott W. Biggins, Guadalupe Garcia‐Tsao, Benedict J. Maliakkal, Jennifer C. Lai, Michael B. Fallon, Hugo E. Vargas, Ram Subramanian, Paul J. Thuluvath, Patrick S. Kamath, Leroy Thack
    Liver Transplantation.2019; 25(6): 870.     CrossRef
  • Factors associated with renal dysfunction in hepatitis C-related cirrhosis and its correlation with Child-Pugh score
    Hamza Waqar Bhatti, Umama Tahir, Noman Ahmed Chaudhary, Sania Bhatti, Muhammad Hafeez, Zuhair Ali Rizvi
    BMJ Open Gastroenterology.2019; 6(1): e000286.     CrossRef
  • Spectrum of hepatitis B and renal involvement
    Apurva S. Shah, Deepak N. Amarapurkar
    Liver International.2018; 38(1): 23.     CrossRef
  • Renal dysfunction in liver cirrhosis and its correlation with Child-Pugh score and MELD score
    G A Siregar, M Gurning
    IOP Conference Series: Earth and Environmental Science.2018; 125: 012214.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications

    Clinical and Molecular Hepatology.2018; 24(3): 230.     CrossRef
  • The prevalence and association of chronic kidney disease and diabetes in liver cirrhosis using different estimated glomerular filtration rate equation
    Cheng-Yi Chen, Cheng-Jui Lin, Chih-Sheng Lin, Fang-Ju Sun, Chi-Feng Pan, Han-Hsiang Chen, Chih-Jen Wu
    Oncotarget.2018; 9(2): 2236.     CrossRef
  • Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit?
    Andrew Davenport, Mohammed Faisal Sheikh, Edmund Lamb, Banwari Agarwal, Rajiv Jalan
    Kidney International.2017; 92(5): 1058.     CrossRef
  • Clinical Outcomes of Peritoneal Dialysis in End-Stage Renal Disease Patients with Liver Cirrhosis: A Propensity Score Matching Study
    Su Mi Lee, Young Ki Son, Seong Eun Kim, Won Suk An
    Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis.2017; 37(3): 314.     CrossRef
  • Appréciation du débit de filtration glomérulaire et de la dysfonction rénale chez le cirrhotique
    C. Mousseaux, A. Bouguerba, S. Ayed, J. Barchasz, M. Boukari, D. Goldgran-Toledano, C. Bornstain, F. Vincent
    Réanimation.2016; 25(S3): 137.     CrossRef
  • Assessment of renal functions in patients of chronic liver disease
    H. K. Aggarwal, Deepak Jain, Suhas Singla, Promil Jain
    Renal Failure.2015; 37(9): 1457.     CrossRef
  • 13,690 View
  • 122 Download
  • 38 Web of Science
  • Crossref

Case Report

Drug rash with eosinophilia and systemic symptoms syndrome following cholestatic hepatitis A: a case report
Jihyun An, Joo Ho Lee, Hyojeong Lee, Eunsil Yu, Dan Bi Lee, Ju Hyun Shim, Sunyoung Yoon, Yumi Lee, Soeun Park, Han Chu Lee
Korean J Hepatol 2012;18(1):84-88.
Published online March 22, 2012
DOI: https://doi.org/10.3350/kjhep.2012.18.1.84

Hepatitis A virus (HAV) infections occur predominantly in children, and are usually self-limiting. However, 75-95% of the infections in adults are symptomatic (mostly with jaundice), with the illness symptoms usually persisting for a few weeks. Atypical manifestations include relapsing hepatitis, prolonged cholestasis, and complications involving renal injury. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, drug-induced hypersensitivity reaction characterized by skin rash, fever, lymph-node enlargement, and internal organ involvement. We describe a 22-year-old male who presented with acute kidney injury and was diagnosed with prolonged cholestatic hepatitis A. The patient also developed DRESS syndrome due to antibiotic and/or antiviral treatment. To our knowledge, this is the first report of histopathologically confirmed DRESS syndrome due to antibiotic and/or antiviral treatment following HAV infection with cholestatic features and renal injury.

Citations

Citations to this article as recorded by  Crossref logo
  • Prolonged Cholestatic Hepatitis A With Transient Epstein-Barr Virus IgM Reactivity and Marked Hyperferritinemia in an HFE H63D Heterozygote
    Sara R Silva, Filipe Dias, Cláudia Ribeiro, Fátima Augusto, Cátia Albino
    Cureus.2026;[Epub]     CrossRef
  • Treatment of Prolonged Cholestasis with Systemic Steroid in Acute Hepatitis A: A Case Report
    Jae Hyun Yoon, Youngeun Seo, Sung Bum Cho
    Convergence Hepatology.2025; 1(1): 85.     CrossRef
  • Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan
    Tatsuo Kanda, Reina Sasaki‐Tanaka, Koji Ishii, Ryosuke Suzuki, Jun Inoue, Atsunori Tsuchiya, Shingo Nakamoto, Ryuzo Abe, Keiichi Fujiwara, Osamu Yokosuka, Tian‐Cheng Li, Satoshi Kunita, Hiroshi Yotsuyanagi, Hiroaki Okamoto
    Hepatology Research.2024; 54(1): 4.     CrossRef
  • DRESS syndrome with cholecystitis in a child: A case report and literature review
    Ferdaous Chahed, Najah Ben Fadhel, Haifa Ben Romdhane, Zohra Chadli, Habib Besbes, Naceur Boughattas, Nadia Ben Fredj, Karim Aouam
    Therapies.2022; 77(5): 622.     CrossRef
  • Characterizing DRESS syndrome recurrence: a systematic review
    Ajay N. Sharma, Samantha Shwe, Vignesh Ravi, Melanie Miller, Natasha A. Mesinkovska, Nathan W. Rojek, Scott Worswick
    Archives of Dermatological Research.2021; 314(8): 721.     CrossRef
  • Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances
    Teresa Bellón
    Drug Safety.2019; 42(8): 973.     CrossRef
  • Variation of clinical manifestations according to culprit drugs in DRESS syndrome
    Da Woon Sim, Ji Eun Yu, Jiung Jeong, Jae‐Woo Jung, Hye‐Ryun Kang, Dong Yoon Kang, Young Min Ye, Young‐Koo Jee, Sujeong Kim, Jung‐Won Park, Min Gyu Kang, Sae Hoon Kim, Hye‐Kyung Park, Min‐Suk Yang, Gyu‐Young Hur, Jun Kyu Lee, Jeong‐Hee Choi, Yong Eun Kwon,
    Pharmacoepidemiology and Drug Safety.2019; 28(6): 840.     CrossRef
  • Allopurinol-induced DRESS syndrome mimicking biliary obstruction
    Hyung Gyu Choi, Junsu Byun, Chae Ho Moon, Jong Ho Yoon, Ki Young Yang, Su Cheol Park, Chul Ju Han
    Clinical and Molecular Hepatology.2014; 20(1): 71.     CrossRef
  • Dress Syndrome Induced by Sulphasalazine
    K. Pałgan, Z. Bartuzi
    European Journal of Inflammation.2014; 12(1): 187.     CrossRef
  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
    S. Ständer, D. Metze, T. Luger, T. Schwarz
    Der Hautarzt.2013; 64(8): 611.     CrossRef
  • 10,541 View
  • 62 Download
  • Crossref

Original Articles

Diagnostic value of cystatin C for predicting acute kidney injury in patients with liver cirrhosis
Mi Yeon Chung, Dae Won Jun, Su Ah Sung
Korean J Hepatol 2010;16(3):301-307.
Published online September 30, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.3.301
Background/Aims

The present study aimed to determine the role of cystatin C as a prognostic factor for acute kidney injury and survival in cirrhotic patients.

Methods

The study investigated 53 liver cirrhosis patients. The renal function was evaluated by serum creatinine, serum and urine cystatin C, and 24-hour creatinine clearance on admission. Acute kidney injury was defined as a serum creatinine level exceeding the normal range (>1.2 mg/dl) and an increase of at least 50% from the baseline value. Multivariate analysis, receiver operating characteristic curve, and survival analysis were used to investigate prognostic factors for acute kidney injury and survival.

Results

Nine of the 53 cirrhotic patients (17.0%) developed acute kidney injury within 3 months. Both serum creatinine and cystatin C were predictive factors for acute kidney injury in univariate analysis, with a diagnostic accuracy of 0.735 (95% confidence interval (CI), 0.525-0.945; p=0.028) for serum cystatin C and 0.698 (95% CI, 0.495-0.901, p=0.063) for creatinine. In multivariate analysis, only serum cystatin C was an independent risk factor for acute kidney injury. The sensitivity and specificity of a serum cystatin C level of >1.23 mg/L to acute kidney injury were 66% and 86%, respectively. Serum cystatin C was positively correlated with the Model for End-Stage Liver Disease (MELD) and MELD-Na scores (r=0.346 and p=0.011, and r=0.427 and p=0.001, respectively). Comparison of the survival rates over the observation period revealed that a serum cystatin C level of >1.23 mg/L was a useful marker for short-term mortality (p<0.001).

Conclusions

The accuracy in predicting acute kidney injury and short-term mortality was higher for a serum cystatin C level of >1.23 mg/L than for the serum creatinine concentration in patients with cirrhosis.

Citations

Citations to this article as recorded by  Crossref logo
  • Nephroprotective potential of robinin to counteract aldicarb induced renal dysfunction via modulating TLR4/MyD88, HMGB1/RAGE, NF-κB pathway: A biochemical and pharmacodynamic approach
    Ning Li, Fuad M. Alzahrani, Mahmoud El Safadi, Sunbal Attaullah, Khalid J. Alzahrani, Faez Falah Alshehri, Arifa Mehreen, Tawaf Ali Shah
    Food and Chemical Toxicology.2025; 197: 115298.     CrossRef
  • Understanding acute kidney injury in cirrhosis: Current perspective
    Sayan Malakar, Sumit Rungta, Arghya Samanta, Umair Shamsul Hoda, Piyush Mishra, Gaurav Pande, Akash Roy, Suprabhat Giri, Praveer Rai, Samir Mohindra, Uday C Ghoshal
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis
    Adrià Juanola, Ann Thu Ma, Koos de Wit, Kohilan Gananandan, Olivier Roux, Giacomo Zaccherini, César Jiménez, Marta Tonon, Cristina Solé, Clara Villaseca, Frank E Uschner, Isabel Graupera, Elisa Pose, Maria José Moreta, Daniela Campion, Ulrich Beuers, Raje
    Gut.2024; 73(1): 156.     CrossRef
  • Predictive value of lipocalin 2 and cystatin C for acute kidney injury in patients with cirrhosis
    Xue-Qing Ma, Si-Si Yang, Huan-Qiu Wang, Jie Wu, Cheng-Bo Yu
    Hepatobiliary & Pancreatic Diseases International.2023; 22(1): 99.     CrossRef
  • Serum Cystatin C within 24 hours after admission: a potential predictor for acute kidney injury in Chinese patients with community acquired pneumonia
    Dawei Chen, Linglin Jiang, Yan Tan, Jing Zhao, Wenjuan Huang, Binbin Pan, Xin Wan
    Renal Failure.2023;[Epub]     CrossRef
  • Hepatorenal Syndrome—Novel Insights into Diagnostics and Treatment
    Krzysztof Badura, Weronika Frąk, Joanna Hajdys, Gabriela Majchrowicz, Ewelina Młynarska, Jacek Rysz, Beata Franczyk
    International Journal of Molecular Sciences.2023; 24(24): 17469.     CrossRef
  • Role of Serum Cystatin C as a Diagnostic Tool for Renal Function in Cirrhotic Patients
    Fathia Elsayed Asal, Mohamed Yousef, Hend Atteya Abdelkhalek Abdraboh, Sherief Abd-Elsalam, Ahmed Abdelaziz Abdelaziz Shama, Mohamed Elbahnasawy, Mohammed H Elnaggar, Hesham Ahmed Alsrogy, Heba Elashry
    The Open Biomarkers Journal.2022;[Epub]     CrossRef
  • Cystatin C in Patients with Acute Kidney Injury after Liver Transplantation
    晓蒙 杨
    Advances in Clinical Medicine.2021; 11(05): 2422.     CrossRef
  • Serum cystatin C as a predictor of 90‐day mortality among patients admitted with complications of cirrhosis
    Anuchit Suksamai, Amnart Chaiprasert, Sakkarin Chirapongsathorn
    JGH Open.2021; 5(5): 607.     CrossRef
  • Cystatin C: best biomarker for acute kidney injury and estimation of glomerular filtration rate in childhood cirrhosis
    Priti Vijay, Bikrant Bihari Lal, Vikrant Sood, Rajeev Khanna, Seema Alam
    European Journal of Pediatrics.2021; 180(11): 3287.     CrossRef
  • Baseline serum cystatin C as a marker of acute kidney injury in patients with acute-on-chronic liver failure
    Praveen Jha, Ashish Kumar Jha, Vishwa Mohan Dayal, Sanjeev Kumar Jha, Amarendra Kumar
    Indian Journal of Gastroenterology.2021; 40(6): 563.     CrossRef
  • Acute kidney injury in children with chronic liver disease
    Akash Deep, Romit Saxena, Bipin Jose
    Pediatric Nephrology.2019; 34(1): 45.     CrossRef
  • Cystatin C predicts acute kidney injury and mortality in cirrhotics: A prospective cohort study
    Rakhi Maiwall, Awinash Kumar, Ankit Bhardwaj, Guresh Kumar, Ajeet S. Bhadoria, Shiv K. Sarin
    Liver International.2018; 38(4): 654.     CrossRef
  • Value of urinary KIM-1 and NGAL combined with serum Cys C for predicting acute kidney injury secondary to decompensated cirrhosis
    Lei Lei, Liang Ping Li, Zhen Zeng, Jing Xi Mu, Xue Yang, Chao Zhou, Zhi Lan Wang, Hu Zhang
    Scientific Reports.2018;[Epub]     CrossRef
  • Can admission serum cystatin C level be an early marker subclinical acute kidney injury in critical care patients?
    Ümmügülsüm Gaygısız, Müge Aydoğdu, Melike Badoğlu, Nazlıhan Boyacı, Zuhal Güllü, Gül Gürsel
    Scandinavian Journal of Clinical and Laboratory Investigation.2016; 76(2): 143.     CrossRef
  • Prognostic value of serum cystatin C levels in cirrhotic patients with normal serum creatinine
    Bilyana Teneva, Emiliya Karaslavova
    Open Medicine.2014; 9(5): 625.     CrossRef
  • Impact of Birth Cohort Screening for Hepatitis C
    Sumeet K. Asrani, Gary L. Davis
    Current Gastroenterology Reports.2014;[Epub]     CrossRef
  • Early Trends in Cystatin C and Outcomes in Patients with Cirrhosis and Acute Kidney Injury
    Justin M. Belcher, Arun J. Sanyal, Guadalupe Garcia-Tsao, Naheed Ansari, Steven G. Coca, Michael G. Shlipak, Chirag R. Parikh
    International Journal of Nephrology.2014; 2014: 1.     CrossRef
  • The impacts of thyroid function on the diagnostic accuracy of Cystatin C to detect acute kidney injury in ICU patients: a prospective, observational study
    Feilong Wang, Wenzhi Pan, Hairong Wang, Yu Zhou, Shuyun Wang, Shuming Pan
    Critical Care.2014;[Epub]     CrossRef
  • Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels
    Dong Jin Kim, Hyun Seok Kang, Hyuk Soon Choi, Hye Jin Cho, Eun Sun Kim, Bora Keum, Hyonggin An, Ji Hoon Kim, Yeon Seok Seo, Yong Sik Kim, Hyung Joon Yim, Yoon Tae Jeen, Hong Sik Lee, Soon Ho Um, Chang Duck Kim, Ho Sang Ryu
    The Korean Journal of Hepatology.2011; 17(2): 130.     CrossRef
  • Cystatin C in Prediction of Acute Kidney Injury: A Systemic Review and Meta-analysis
    Zhongheng Zhang, Baolong Lu, Xiaoyan Sheng, Ni Jin
    American Journal of Kidney Diseases.2011; 58(3): 356.     CrossRef
  • 13,078 View
  • 81 Download
  • Crossref
Prevalence of Hepatitis G Virus Infection in Patients with Chronic Renal Failure
Woo-Won Shin, M.D., Kyung-Ha Song, M.D., Jeong-Hwan Cho, M.D., Hyun-Sook Ahn*, Sung-Wook Lee, M.D., Dong-Joo Keum, M.D., Sung-Jin Bae, M.D.†, Sun-Taec Kim, M.D.†, Kwang-Yul Chang, M.D., Jung-Ha Park, M.D., Myung-Hwan Noh, M.D., Seong-Eun Kim, M.D., Sang-Young Han, M.D., Seok-Reyol Choi, M.D., and Ki-Hyun Kim, M.D.
Korean J Hepatol 2000;6(1):82-90.
Backgrounds/Aims
: To investigate the prevalence and clinical implications of hepatitis G virus (HGV) infection in patients with chronic renal failure, a cross-sectional study of 131 hemodialysis patients and 33 kidney transplantation recipients was conducted. Methods : HGV RNA was amplified by reverse-transcription (RT) polymerase chain reaction (PCR) assay with primers from the 5'-untranslated region of the viral genome. Results : The prevalence of HGV infection in patients with chronic renal failure was 25%(41/164). The following factors were taken into consideration: the mean age(43.15±11.97 years vs 46.46±13.08 years), the male to female ratio(2.15:1 vs 1.86:1), the mean of the dialysis duration(4.58±3.18 years vs 3.90±3.31 years), transfusion history (75.6% vs 62.6%), the mean of the ALT level during the prior 6 months(25.78±21.50 IU/L vs 23.00±59.49 IU/L), and the amount of transfusion(6.22±8.03 units vs 5.74±9.44 units). The anti-HCV(4.88% vs 8.94%) showed no difference between HGV RNA positive and negative group. The HBsAg positive ratio was 19.5% and 5.81% in HGV RNA positive group and negative group, respectively. Conclusion : The prevalence of HGV infection in patients with chronic renal failure was 25%. There was a higher rate of HBsAg positivity in the HGV RNA positive group rather than in the negative group. HGV infection did not seem to be associated with clinically significant hepatitis.(Korean J Hepatol 2000;6:82-90)
  • 3,533 View
  • 17 Download

Case Report

Two Cases of Congenital Hepatic Fibrosis with Polycystic Kidney Disease
Dong Hyun Lee,Ok Nyu Kong,Ji Young Kim,Chan Won Park,Jae Hyeon Moon,Dae Gun Nam,Hyung Jun Chu,Dae Hwan Kang,Geun Am Song,Mong Cho,Ung Suk Yang
Korean J Hepatol 2001;7(4):485-490.
Congenital hepatic fibrosis(CHF) is a rare development abnormality, which is characterized pathologically by periportal fibrosis with irregularly shaped proliferating bile ducts. In most, if not all. cases CHF is associated with autosomal recessive polycystic kidney disease. Recently, we experienced two cases, confirmed by percutaneous needle liver biopsy, of CHF with polycystic kidney disease. The first patient was a 19-year-old man and presented with hematemesis and hepatosplenomegaly. Esophageal varix was noted by an endoscopic examination and an endoscopic variceal ligation was performed. Abdominal CT scanning revealed innumerable cysts of both kidneys. The patient also had cystic dilation of subarchnoid space in the basal ciatern and posterrior fossa detected through brain MRI. The second patient was a 24-year-old man admitted for an evaluation of splenomegaly. Ha had no esophageal varix but, splenic varix and splenorenal shunt were detected through an abdominal CT scanning. Innumerable renal cysts were also present. The diagnosis of CHF was confirmed in both cases by its typical histologic features. We report these cases with a review of the relevant literatures. (Korean J Hepatol 2001;7 :485 - 490)
  • 3,276 View
  • 17 Download
Original Article
Clinical Features of Acute Viral Hepatitis A Complicated with Acute Renal Failure
Kee Sup Song, M.D., Min Ju Kim, M.D., Chang Soo Jang, M.D., Hyuk Sang Jung, M.D., Hyun Hee Lee, M.D., Oh Sang Kwon, M.D., Yun Soo Kim, M.D., Duck Joo Choi, M.D., Ju Hyun Kim, M.D., Seung Yeon Ha, M.D.1
Korean J Hepatol 2007;13(2):166-173.
Background
Most patients with acute viral hepatitis A (AVHA) spontaneously recover, but a few patients experience complications. This study was carried out to examine clinical features of AVHA complicated with acute renal failure (ARF). Method: Medical records of 404 patients with AVHA were reviewed. Clinical features of AVHA patients with ARF (group A) were compared with those of AVHA patients without ARF (group B). Result: ARF complication was present in 11 patients (3%). There were no differences between group A and B in sex ratio and age. Microscopic hematuria (7 cases), proteinuria (7 cases), metabolic acidosis (4 cases), oliguria (4 cases), pulmonary edema (3 cases) and hyperkalemia (2 cases) were found in group A. The prevalence of heavy alcohol drinking (64% vs 3%, p<0.001) and diabetes mellitus (18% vs 1%, p=0.01) was higher in group A than B. The peak value of ALT (median: 4,290 IU/L vs 1,266 IU/L, p=0.006) and total bilirubin (median: 10.8 mg/dL vs 6.0 mg/dL, p=0.001) was higher in group A than B. Duration of admission was longer in group A than B (median: 14 days vs 5 days, p<0.001). Four patients of group A recovered with renal replacement therapy, while 7 patients recovered with conservative treatment. Conclusions: The AVHA patients with ARF experienced more severe hepatitis than those without ARF, but they had a good prognosis with the proper treatment. (Korean J Hepatol 2007;13:166-173)
  • 4,371 View
  • 35 Download